Case number 1:19-cv-02053
Novartis Pharmaceuticals Corporation v. Hetero USA Inc.. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Aug 12, 2024 | 434 | Notice of Appeal* (1) |
| Jun 21, 2024 | 417 | ORDER Granting Joint Motion for Indicative Ruling to Enter Vacatur as to Hetero Pursuant to Federal Rules of Civil Procedure 62.1 and 60(b) and Enter Consent Judgment and Order of Injunction (D.I. 1376 in 20-md-2930-RGA; D.I. 415 in 19-cv-2053-RGA). Signed by Judge Richard G. Andrews on 6/21/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) Modified on 6/27/2024 (nms). (Entered: 06/21/2024) (4) |
| Jun 12, 2024 | 416 | REDACTED VERSION of 415 Joint Motion for Indicative Ruling to Enter Vacatur as to Hetero Pursuant to Federal Rules of Civil Procedure 62.1 and 60(b) and Enter Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/12/2024 (nms). (Entered: 06/12/2024) (14) |
| Jun 4, 2024 | 415 | [SEALED] Joint Motion for Indicative Ruling to Enter Vacatur as to Hetero Pursuant to Federal Rules of Civil Procedure 62.1 and 60(b) and Enter Consent Judgment and Order of Injunction - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Silver, Daniel) Modified on 6/5/2024 (nms). (Entered: 06/04/2024) (0) |
| Mar 6, 2024 | 414 | ORDER of USCA for the Federal Circuit as to [ 407 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. Decision of USCA: Appeal No. 2023-2260 is deconsolidated from Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221, and Appeal No. 2023-2260 is dismissed. Each side shall bear its own costs regarding Appeal No. 2023-2260. The stay in Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221 is lifted. The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221. (nms) (Entered: 03/06/2024) (3) |
| Aug 14, 2023 | 413 | MOTION for Pro Hac Vice Appearance of Attorney Deanne E. Maynard of Morrison & Forester LLP - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 08/14/2023) (4) |
| Aug 11, 2023 | 412 | NOTICE of Lodging of Trial Demonstrative Exhibits by Novartis Pharmaceuticals Corporation (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Silver, Daniel) (Entered: 08/11/2023) (0) |
| Aug 2, 2023 | 410 | ORAL ORDER: The redacted filing (D.I. 409 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filing is DUE within five business days. Ordered by Judge Richard G. Andrews on 8/2/2023. (nms) (Entered: 08/02/2023) (0) |
| Aug 2, 2023 | 411 | REDACTED VERSION of 404 Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Stipulation)(Weinblatt, Richard) Modified on 8/3/2023 (nms). (Entered: 08/02/2023) (0) |
| Aug 1, 2023 | 408 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 407 Notice of Appeal (Federal Circuit), filed by Novartis Pharmaceuticals Corporation. USCA Case Number 2023-2221. (nms) (Entered: 08/01/2023) (4) |
| Aug 1, 2023 | 409 | REDACTED VERSION of 404 Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Stipulation)(Weinblatt, Richard) Modified on 8/2/2023 (nms). (Entered: 08/01/2023) (0) |
| Jul 24, 2023 | 407 | NOTICE OF APPEAL to the Federal Circuit of 406 Judgment . Appeal filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 07/24/2023) (3) |
| Jul 21, 2023 | 406 | FINAL JUDGMENT Regarding U.S. Patent No. 8,101,659 (see Judgment for further details). Signed by Judge Richard G. Andrews on 7/21/2023. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 07/21/2023) (5) |
| Jul 20, 2023 | 405 | PROPOSED Final Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/21/2023 (nms). (Entered: 07/20/2023) (5) |
| Jul 19, 2023 | 404 | [SEALED] Letter to The Honorable Leonard P. Stark, from Richard C. Weinblatt, regarding request for judicial assistance. (Attachments: # 1 Stipulation)(Weinblatt, Richard) Modified on 7/20/2023 (nms). (Main Document 404 replaced on 7/20/2023) (nms). (Entered: 07/19/2023) (0) |
| Jul 14, 2023 | 403 | STIPULATION and Proposed Order to Extend Time to submit a Proposed Final Judgment to July 20, 2023 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/17/2023 (nms). (Entered: 07/14/2023) (3) |
| Jul 7, 2023 | 402 | TRIAL OPINION (Regarding the '659 Patent): For the foregoing reasons, I find the asserted claims of the '659 Patent invalid for lack of written description. The parties shall submit a final judgment consistent with this memorandum opinion within one week (see Opinion for further details). Signed by Judge Richard G. Andrews on 7/7/2023. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) Modified on 7/11/2023 (nms). (Entered: 07/07/2023) (46) |
| Jul 5, 2023 | 401 | REDACTED VERSION of 399 Stipulation and Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/6/2023 (nms). (Entered: 07/05/2023) (4) |
| Jun 30, 2023 | 400 | [SEALED] ORDER Granting (1089 in 20-md-2930-RGA; 89 in 21-cv-1760-RGA; 399 in 19-cv-2053-RGA; 174 in 21-cv-1330-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/30/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA(nms) (Entered: 06/30/2023) (0) |
| Jun 29, 2023 | 398 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Main Document) (4) |
| Jun 29, 2023 | 399 | [SEALED] STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/29/2023) (0) |
| Jun 29, 2023 | 398 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Certification for Melinda R. Roberts) (1) |
| May 3, 2023 | 397 | REDACTED VERSION of 395 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2023 (nms). (Entered: 05/03/2023) (5) |
| Apr 26, 2023 | 395 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/26/2023 (nms). (Entered: 04/26/2023) (0) |
| Apr 26, 2023 | 396 | [SEALED] Consent Judgment and Order of Injunction (between Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd. and Novartis Pharmaceuticals Corporation). Signed by Judge Richard G. Andrews on 4/26/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA, 1:21-cv-01330-RGA, 1:22-cv-00498-RGA(nms) (Entered: 04/26/2023) (0) |
| Apr 14, 2023 | 394 | NOTICE of Appearance by Daniel Taylor on behalf of Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc. (Taylor, Daniel) (Entered: 04/14/2023) (2) |
| Apr 10, 2023 | 393 | REDACTED VERSION of 390 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/10/2023 (nms). (Entered: 04/10/2023) (4) |
| Apr 4, 2023 | 392 | STIPULATION and Proposed Order to Extend Time to file a public redacted version of the parties Proposed Consent Judgment and Order of Injunction to April 12, 2023 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/5/2023 (nms). (Entered: 04/04/2023) (2) |
| Mar 30, 2023 | 391 | [SEALED] CONSENT Judgment and Order of Injunction between Novartis Pharmaceuticals Corporation, and Novugen Pharma (Malaysia) Sdn. Bhd.. Signed by Judge Richard G. Andrews on 3/30/2023.*This order will be emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) (Entered: 03/30/2023) (0) |
| Mar 29, 2023 | 390 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 3/29/2023 (nms). (Entered: 03/29/2023) (0) |
| Mar 22, 2023 | 389 | NOTICE of Change of Address by Alexandra M. Joyce (Joyce, Alexandra) (Entered: 03/22/2023) (5) |
| Mar 17, 2023 | 388 | NOTICE of Withdrawal of Appearance of Delaware Counsel, Eve Ormerod by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hetero USA Inc., (Ormerod, Eve) (Entered: 03/17/2023) (3) |
| Jan 24, 2023 | 386 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding hyperlinked post-trial briefs for the 659 patent. (Silver, Daniel) Modified on 1/25/2023 (nms). (Entered: 01/24/2023) (1) |
| Jan 24, 2023 | 387 | Letter to the Honorable Richard G. Andrews, from Stamatios Stamoulis, regarding hyperlinked post-trial briefs for the 659 patent. (Stamoulis, Stamatios) Modified on 1/25/2023 (nms). (Entered: 01/24/2023) (1) |
| Jan 13, 2023 | 385 | POST-Trial Reply Brief re Invalidity, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) Modified on 1/13/2023 (nms). (Entered: 01/13/2023) (26) |
| Jan 6, 2023 | 384 | REDACTED VERSION of 369 Unopposed Motion to Redact Portions of the June 3, 2022 Discovery Hearing, by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Stamoulis, Stamatios) Modified on 1/9/2023 (nms). (Entered: 01/06/2023) (Main Document) (6) |
| Jan 6, 2023 | 384 | REDACTED VERSION of 369 Unopposed Motion to Redact Portions of the June 3, 2022 Discovery Hearing, by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Stamoulis, Stamatios) Modified on 1/9/2023 (nms). (Entered: 01/06/2023) (Exhibit A) (30) |
| Jan 6, 2023 | 384 | REDACTED VERSION of 369 Unopposed Motion to Redact Portions of the June 3, 2022 Discovery Hearing, by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Stamoulis, Stamatios) Modified on 1/9/2023 (nms). (Entered: 01/06/2023) (Exhibit B) (30) |
| Dec 16, 2022 | 381 | ORDER: The motion to redact (D.I. 369 in 19-cv-2053-RGA; D.I. 859 in 20-md-2930-RGA) is DENEID. The transcript of the June 3rd hearing (D.I. 755 in 20md2930) is UNSEALED. Signed by Judge Richard G. Andrews on 12/16/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) (Entered: 12/16/2022) (2) |
| Dec 16, 2022 | 382 | POST-TRIAL Answering Brief on the Validity of the '659 Patent, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/18/2022 (nms). (Entered: 12/16/2022) (30) |
| Dec 16, 2022 | 383 | Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 12/16/2022) (30) |
| Dec 15, 2022 | 380 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Main Document) (5) |
| Dec 15, 2022 | 380 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 1) (30) |
| Dec 15, 2022 | 380 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 2) (30) |
| Dec 15, 2022 | 380 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 3) (30) |
| Dec 15, 2022 | 380 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 4) (30) |
| Dec 15, 2022 | 380 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 5) (13) |
| Dec 15, 2022 | 380 | NOTICE of Lodging of Defendants' Trial Demonstratives used during the trial held September 12-14, 2022, by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Gattuso, Dominick) Modified on 12/15/2022 (nms). (Entered: 12/15/2022) (Exhibit 6) (9) |
| Nov 4, 2022 | 374 | STIPULATION and [Proposed] Order Regarding Post-Trial Briefing for U.S. Patent No. 8,796,331 by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/04/2022) (6) |
| Nov 4, 2022 | 375 | POST Trial Brief Regarding the '659 Patent, by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 11/4/2022 (nms). (Main Document 375 replaced on 11/7/2022) (nms). (Entered: 11/04/2022) (30) |
| Nov 4, 2022 | 376 | Proposed Findings of Fact Regarding the '659 Patent, by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 11/4/2022 (nms). (Main Document 376 replaced on 11/7/2022) (nms). (Main Document 376 replaced on 1/17/2023) (nms). (Entered: 11/04/2022) (30) |
| Nov 4, 2022 | 379 | SO ORDERED Granting (D.I. 374 in 19-cv-2053-RGA; D.I. 598 in 19-cv-1979-RGA; D.I. 226 in 19-cv-2021-RGA; D.I. 886 in 20-md-2930-RGA) Stipulation and Proposed Order Regarding Post-Trial Briefing for U.S. Patent No. 8,796,331. Signed by Judge Richard G. Andrews on 11/4/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 11/04/2022) (6) |
| Nov 1, 2022 | 370 | Official Transcript of Pretrial Conference held on 9/1/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/22/2022. Redacted Transcript Deadline set for 12/2/2022. Release of Transcript Restriction set for 1/30/2023. (Triozzi, Heather) (Entered: 11/01/2022) (50) |
| Nov 1, 2022 | 371 | Official Transcript of Bench Trial held on 9/12/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/22/2022. Redacted Transcript Deadline set for 12/2/2022. Release of Transcript Restriction set for 1/30/2023. (Triozzi, Heather) (Entered: 11/01/2022) (267) |
| Nov 1, 2022 | 372 | Official Transcript of Bench Trial held on 9/13/22 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/22/2022. Redacted Transcript Deadline set for 12/2/2022. Release of Transcript Restriction set for 1/30/2023. (Triozzi, Heather) (Entered: 11/01/2022) (240) |
| Nov 1, 2022 | 373 | Official Transcript of Bench Trial held on 9/14/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/22/2022. Redacted Transcript Deadline set for 12/2/2022. Release of Transcript Restriction set for 1/30/2023. (Triozzi, Heather) (Entered: 11/01/2022) (63) |
| Oct 11, 2022 | 369 | [SEALED] Unopposed Motion to Redact Portions of the June 3, 2022 Discovery Hearing - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Stamoulis, Stamatios) Modified on 10/11/2022 (nms). (Entered: 10/11/2022) (0) |
| Sep 26, 2022 | 368 | SO ORDERED Granting (D.I. 564 in 19-cv-1979-RGA; D.I. 220 in 19-cv-2021-RGA; D.I. 367 in 19-cv-2053-RGA; D.I. 839 in 20-md-2930-RGA) Stipulation and Order Regarding Post-Trial Briefing. Signed by Judge Richard G. Andrews on 9/26/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 09/26/2022) (6) |
| Sep 23, 2022 | 367 | STIPULATION and Order Regarding Post Trial Briefing by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) (Entered: 09/23/2022) (6) |
| Sep 22, 2022 | 365 | REDACTED VERSION of 356 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/23/2022 (nms). (Entered: 09/22/2022) (5) |
| Sep 22, 2022 | 366 | REDACTED VERSION of 357 Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/23/2022 (nms). (Entered: 09/22/2022) (4) |
| Sep 21, 2022 | 361 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding courtesy copies of the exhibits. (Silver, Daniel) (Entered: 09/21/2022) (1) |
| Sep 21, 2022 | 362 | REDACTED VERSION of 336 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-12B)(Silver, Daniel) Modified on 9/21/2022 (nms). (Entered: 09/21/2022) (Main Document) (30) |
| Sep 21, 2022 | 363 | REDACTED VERSION of 347 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/21/2022 (nms). (Entered: 09/21/2022) (30) |
| Sep 21, 2022 | 364 | STIPULATION TO EXTEND TIME for the parties to submit a post-trial briefing schedule, from September 21, 2022 to September 23, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc.. (Ormerod, Eve) (Entered: 09/21/2022) (5) |
| Sep 21, 2022 | 362 | REDACTED VERSION of 336 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-12B)(Silver, Daniel) Modified on 9/21/2022 (nms). (Entered: 09/21/2022) (Exhibit 1-12B) (30) |
| Sep 20, 2022 | 359 | Admitted Trial Exhibits for Bench Trial held 9/12/2022, through 9/14/2022, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/20/2022 (nms). (Entered: 09/20/2022) (15) |
| Sep 20, 2022 | 360 | NOTICE of Redaction Request, by Stamatios Stamoulis. (Stamoulis, Stamatios) Modified on 9/21/2022 (nms). Modified on 10/4/2022 (nms). (Entered: 09/20/2022) (2) |
| Sep 16, 2022 | 357 | [SEALED] CONSENT JUDGMENT and Order of Injunction relating to Defendant Zydus. Signed by Judge Richard G. Andrews on 9/16/2022.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA, 1:22-cv-00440-RGA(nms) (Entered: 09/16/2022) (0) |
| Sep 16, 2022 | 358 | STIPULATION and Proposed Order to Extend Time to file redacted versions of (1) Proposed Joint Pretrial Order, (2) Revised Proposed Joint Pretrial Order, (3) Suggestion of Remand Proposed Order to September 21, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/16/2022 (nms). (Entered: 09/16/2022) (6) |
| Sep 15, 2022 | 355 | MULTI MEDIA DOCUMENT in the form of a USB drive containing video depositions for trial witnesses Piotr Kapinski, Ph.D. and Dr. Randy Lee Webb. Filing related to (D.I. 353 in 19-cv-2053-RGA; D.I. 546 in 19-cv-1979-RGA; D.I. 812 in 20-md-2930-RGA; D.I. 211 in 19-cv-2021-RGA) Notice of Lodging of Multimedia Filing. (Media on file in Clerk's Office). Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 09/15/2022) (0) |
| Sep 15, 2022 | 356 | [SEALED] Proposed Consent Judgment and Order of Injunction as to Defendant Zydus, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 9/15/2022 (nms). (Entered: 09/15/2022) (0) |
| Sep 14, 2022 | 353 | NOTICE of Lodging of Multimedia Filing by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Letter)(Gattuso, Dominick) Modified on 9/15/2022 (nms). (Entered: 09/14/2022) (Main Document) (4) |
| Sep 14, 2022 | 354 | Witness List for Bench Trial held 9/12/2022, through 9/14/2022. (nms) (Entered: 09/14/2022) (3) |
| Sep 14, 2022 | 353 | NOTICE of Lodging of Multimedia Filing by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Attachments: # 1 Letter)(Gattuso, Dominick) Modified on 9/15/2022 (nms). (Entered: 09/14/2022) (Cover Letter) (1) |
| Sep 9, 2022 | 352 | MEMORANDUM ORDER Denying Plaintiff's Motion to Preclude Portions of Dr. Fintel's Testimony (see Memorandum Order for further details). Signed by Judge Richard G. Andrews on 9/9/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 09/09/2022) (3) |
| Sep 7, 2022 | 348 | ORDER AFTER PRETRIAL CONFERENCE (see Order for further details). Signed by Judge Richard G. Andrews on 9/7/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 09/07/2022) (2) |
| Sep 7, 2022 | 349 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding enclosing Curriculum Vitae for experts. (Attachments: # 1 Curriculum Vitae for Francis G. Spinale, # 2 Curriculum Vitae for Alexander M. Klibanov)(Silver, Daniel) (Entered: 09/07/2022) (Main Document) (1) |
| Sep 7, 2022 | 350 | [SEALED] ORDER Granting Joint Pretrial Order (D.I. 243 in 20-cv-445-RGA; D.I. 769 in 20-md-2930-RGA; D.I. 204 in 19-cv-2021-RGA; D.I. 534 in 19-cv-1979-RGA: D.I. 347 in 19-cv-2053-RGA). Signed by Judge Richard G. Andrews on 9/7/2022.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 09/07/2022) (0) |
| Sep 7, 2022 | 351 | Letter to The Honorable Richard G. Andrews from Dominick T. Gattuso, Esquire regarding CV of Experts. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit)(Gattuso, Dominick) (Entered: 09/07/2022) (Main Document) (1) |
| Sep 7, 2022 | 351 | Letter to The Honorable Richard G. Andrews from Dominick T. Gattuso, Esquire regarding CV of Experts. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit)(Gattuso, Dominick) (Entered: 09/07/2022) (Exhibit) (19) |
| Sep 7, 2022 | 351 | Letter to The Honorable Richard G. Andrews from Dominick T. Gattuso, Esquire regarding CV of Experts. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit)(Gattuso, Dominick) (Entered: 09/07/2022) (Exhibit) (21) |
| Sep 7, 2022 | 351 | Letter to The Honorable Richard G. Andrews from Dominick T. Gattuso, Esquire regarding CV of Experts. (Attachments: # 1 Exhibit, # 2 Exhibit, # 3 Exhibit)(Gattuso, Dominick) (Entered: 09/07/2022) (Exhibit) (29) |
| Sep 7, 2022 | 349 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding enclosing Curriculum Vitae for experts. (Attachments: # 1 Curriculum Vitae for Francis G. Spinale, # 2 Curriculum Vitae for Alexander M. Klibanov)(Silver, Daniel) (Entered: 09/07/2022) (Curriculum Vitae for Francis G. Spinale) (30) |
| Sep 7, 2022 | 349 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding enclosing Curriculum Vitae for experts. (Attachments: # 1 Curriculum Vitae for Francis G. Spinale, # 2 Curriculum Vitae for Alexander M. Klibanov)(Silver, Daniel) (Entered: 09/07/2022) (Curriculum Vitae for Alexander M. Klibanov) (30) |
| Sep 6, 2022 | 343 | Joint Letter to The Honorable Richard G. Andrews from Adam W. Poff regarding Commercial Success Experts. (Poff, Adam) (Entered: 09/06/2022) (2) |
| Sep 6, 2022 | 344 | REDACTED VERSION of 334 MOTION in Limine to Preclude Dr. Steed's Written Description Opinions Concerning the Characterization of LCZ696 the Rely on Irrelevant Material, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (17) |
| Sep 6, 2022 | 345 | REDACTED VERSION of 335 Appendix, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (30) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Main Document) (30) |
| Sep 6, 2022 | 347 | [SEALED] Proposed Pretrial Order (*dispute Paragraph 174), by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/7/2022 (nms). (Entered: 09/06/2022) (0) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 2 of 10) (30) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 3 of 10) (30) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 4 of 10) (30) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 5 of 10) (12) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 6 of 10) (30) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 7 of 10) (30) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 8 of 10) (26) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 9 of 10) (29) |
| Sep 6, 2022 | 346 | REDACTED VERSION of 333 Appendix, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2, # 2 Part 3, # 3 Part 4, # 4 Part 5, # 5 Part 6, # 6 Part 7, # 7 Part 8, # 8 Part 9, # 9 Part 10)(Joyce, Alexandra) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (Pt. 10 of 10) (30) |
| Sep 1, 2022 | 342 | ORAL ORDER: The motion to strike new infringement opinions of Dr. Park (D.I. 598 in 20-md-02930-RGA) is RESOLVED as stated in the transcript of the June 3, 2022 hearing. (D.I. 755 at 23-26). Ordered by Judge Richard G. Andrews on 9/1/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) (Entered: 09/01/2022) (0) |
| Aug 31, 2022 | 341 | REDACTED VERSION of 331 Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/31/2022 (nms). (Entered: 08/31/2022) (5) |
| Aug 26, 2022 | 339 | ORDER SETTING TRIAL DATES: Trial on the validity of U.S. Patent Nos. 8,101,659 (the 659 patent) and 8,796,331 (the 331 patent) is scheduled for September 12 to September 14, 2022, beginning each day at 8:30 a.m., and ending each day by 5:00 p.m. Trial on the validity of U.S. Patent Nos. 8,877,938 (the 938 patent) and 9,388,134 (the 134 patent) is scheduled for October 18, 2022, beginning at 8:30 a.m. and ending by 5:00 p.m. (see Order for further details). Signed by Judge Richard G. Andrews on 8/26/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA(nms) (Entered: 08/26/2022) (4) |
| Aug 26, 2022 | 340 | REDACTED VERSION of 327 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/26/2022 (nms). (Entered: 08/26/2022) (10) |
| Aug 25, 2022 | 337 | [SEALED] ORDER Granting (D.I. 732 in 20-md-2930-RGA; D.I. 331 in 19-cv-2053-RGA) Stipulation and [Proposed] Order Regarding Defendant Zydus's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331. Signed by Judge Richard G. Andrews on 8/25/2022.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) (Entered: 08/25/2022) (0) |
| Aug 25, 2022 | 338 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Proposed Order Setting the Schedule for the Trial Dates. (Attachments: # 1 Text of Proposed Order Setting Trial Dates)(Joyce, Alexandra) (Entered: 08/25/2022) (Main Document) (4) |
| Aug 25, 2022 | 338 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Proposed Order Setting the Schedule for the Trial Dates. (Attachments: # 1 Text of Proposed Order Setting Trial Dates)(Joyce, Alexandra) (Entered: 08/25/2022) (Text of Proposed Order Setting Trial Dates) (4) |
| Aug 24, 2022 | 331 | [SEALED] STIPULATION and [Proposed] Order Regarding Defendant Zydus's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331 by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 08/24/2022) (0) |
| Aug 24, 2022 | 332 | MOTION in Limine to Preclude Defendants' Reliance on Non-Prior Art Documents as Evidence of the State of the Art and a POSA's Understanding - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 8/24/2022 (nms). (Entered: 08/24/2022) (16) |
| Aug 24, 2022 | 333 | [SEALED] APPENDIX re 332 MOTION in Limine to Preclude Defendants' Reliance on Non-Prior Art Documents as Evidence of the State of the Art and a POSA's Understanding, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-19 part 1, # 2 Exhibits 1-19 part 2, # 3 Exhibits 1-19 part 3, # 4 Exhibits 1-19 part 4, # 5 Exhibits 1-19 part 5, # 6 Exhibits 1- 19 part 6, # 7 Exhibits 1-19 part 7, # 8 Exhibits 1-19 part 8, # 9 Exhibits 1-19 part 9, # 10 Exhibits 1-19 part 10, # 11 Exhibits 1-19 part 11, # 12 Certificate of Service)(Silver, Daniel) Modified on 8/24/2022 (nms). (Entered: 08/24/2022) (0) |
| Aug 24, 2022 | 334 | [SEALED] MOTION in Limine to Preclude Dr. Steed's Written Description Opinions Concerning the Characterization of LCZ696 the Rely on Irrelevant Material - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 8/24/2022 (nms). (Entered: 08/24/2022) (0) |
| Aug 24, 2022 | 335 | [SEALED] APPENDIX re 334 MOTION in Limine to Preclude Dr. Steed's Written Description Opinions Concerning the Characterization of LCZ696 the Rely on Irrelevant Material, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-11 part 1, # 2 Exhibits 1-11 part 2, # 3 Certificate of Service)(Silver, Daniel) Modified on 8/24/2022 (nms). (Entered: 08/24/2022) (0) |
| Aug 24, 2022 | 336 | [SEALED] Proposed Pretrial Order by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 1B, # 3 Exhibit 1F, # 4 Exhibit 1I, # 5 Exhibit 2, # 6 Exhibit 3, # 7 Exhibit 3B, # 8 Exhibit 3F, # 9 Exhibit 3I, # 10 Exhibit 4, # 11 Exhibit 5, # 12 Exhibit 5A, # 13 Exhibit 6, # 14 Exhibit 6B, # 15 Exhibit 7, # 16 Exhibit 7B, # 17 Exhibit 8, # 18 Exhibit 8B, # 19 Exhibit 9, # 20 Exhibit 10, # 21 Exhibit 10B, # 22 Exhibit 11, # 23 Exhibit 12, # 24 Exhibit 12B)(Silver, Daniel) (Entered: 08/24/2022) (0) |
| Aug 18, 2022 | 329 | ORAL ORDER: The Pretrial Conference in advance of the invalidity trial is now rescheduled for 9/1/2022, at 3:30 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 8/18/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 08/18/2022) (0) |
| Aug 18, 2022 | 330 | MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc.. (Stamoulis, Stamatios) (Entered: 08/18/2022) (5) |
| Aug 17, 2022 | 328 | ORAL ORDER: Due to a scheduling conflict the Pretrial Conference set for 8/26/2022, is CANCELED. The conference will be rescheduled for a date to be determined. Ordered by Judge Richard G. Andrews on 8/17/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) (Entered: 08/17/2022) (0) |
| Aug 16, 2022 | 327 | [SEALED] Joint Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Scheduling of the Three-Day Validity Trial for United States Patent Nos. 8,101,659 (the '659 patent), 8,796,331 (the '331 patent), 8,877,938 (the '938 patent), and 9,388,134 (the '134 patent). (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 08/16/2022) (0) |
| Aug 12, 2022 | 325 | REDACTED VERSION of 323 Order Regarding Defendant Hetero's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc.. (Belgam, Neal) Modified on 8/13/2022 (nms). (Entered: 08/12/2022) (4) |
| Aug 12, 2022 | 326 | NOTICE of Pursuant to 35 U.S.C. § 282, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Ferraro, April) Modified on 8/13/2022 (nms). (Entered: 08/12/2022) (15) |
| Aug 5, 2022 | 324 | ORAL ORDER: A 2 day bench trial on infringement regarding the '938 and '134 patents between Plaintiff and Defendants Crystal and Zydus is now set to start on 10/13/2022, at 8:30 AM in Courtroom 6A. A pretrial conference in advance of the trial will be held on 9/30/2022, at 9:00 AM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 8/5/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02053-RGA(nms) (Entered: 08/05/2022) (0) |
| Aug 4, 2022 | 322 | [SEALED] STIPULATION and [Proposed] Order Regarding Defendant Hetero's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331 by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 08/04/2022) (0) |
| Aug 4, 2022 | 323 | [SEALED] ORDER Granting (D.I. 322 in 19-cv-2053-RGA; 707 in 20-md-2930-RGA) Stipulation and Proposed Order Regarding Defendant Hetero's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331. Signed by Judge Richard G. Andrews on 8/4/2022.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) (Entered: 08/04/2022) (0) |
| Aug 3, 2022 | 321 | Letter (2) Docket Text: Letter to The Honorable Richard G. Andrews from Adam W. Poff regarding '659 and '331 patent infringement trial. (Poff, Adam) |
| Jul 26, 2022 | 319 | Redacted Document (8) Docket Text: REDACTED VERSION of [308] Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/26/2022 (nms). |
| Jul 26, 2022 | 320 | Main Document (409) Docket Text: REDACTED VERSION of [309] Declaration, by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Part 2, # (2) Part 3, # (3) Part 4)(Joyce, Alexandra) Modified on 7/26/2022 (nms). |
| Jul 26, 2022 | 320 | Pt. 2 of 4 (41) |
| Jul 26, 2022 | 320 | Pt. 3 of 4 (173) |
| Jul 26, 2022 | 320 | Pt. 4 of 4 (125) |
| Jul 25, 2022 | 318 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Supplemental Expert Report of Robin D. Rogers, Ph.D. Against Crystal Pharmaceutical (Suzhou) Co., Ltd., Mylan Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 22, 2022 | 314 | Notice of Appearance (4) Docket Text: NOTICE of Appearance by Alexis Stombaugh on behalf of Zydus Lifesciences Ltd., Zydus Pharmaceuticals (USA) Inc. (Stombaugh, Alexis) |
| Jul 22, 2022 | 315 | Reply Brief (16) Docket Text: REPLY BRIEF re [304] MOTION to Preclude Defendants' Expert Dr. Fintel from Offering Opinions on Topics Outside His Expertise, filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/24/2022 (nms). |
| Jul 22, 2022 | 316 | Main Document (4) Docket Text: DECLARATION of Shannon K. Clark, Esq. re [315] Reply Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits I-M)(Silver, Daniel) Modified on 7/24/2022 (nms). Modified on 7/24/2022 (nms). |
| Jul 22, 2022 | 316 | Exhibit I-M (75) |
| Jul 22, 2022 | 317 | Redacted Document (30) Docket Text: REDACTED VERSION of [311] Answering Brief in Opposition, by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.. (Hoeschen, Nathan) Modified on 7/24/2022 (nms). |
| Jul 21, 2022 | 313 | Order (6) Docket Text: SO ORDERED Granting (D.I. 312 in 19-cv-2053-RGA; D.I. 488 in 19-cv-1979-RGA; D.I. 15 in 20-cv-445-RGA; D.I. 690 in 20-md-2930-RGA) Stipulation Regarding Supplemental Expert Reports of Dr. Friscic and Dr. Rogers. Signed by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) |
| Jul 20, 2022 | 312 | Stipulation (6) Docket Text: STIPULATION Regarding Supplemental Expert Reports of Dr. Friscic and Dr. Rogers by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Jul 14, 2022 | 310 | Status Report (9) Docket Text: Joint Status Report, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/15/2022 (nms). |
| Jul 12, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 479 in 19-cv-1979-RGA; D.I. 208 in 20-cv-445-RGA; D.I. 674 in 20-md-2930-RGA; D.I. 177 in 19-cv-2021-RGA; D.I. 306 in 19-cv-2053-RGA) Stipulation and Proposed Order to Extend Time Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) |
| Jul 11, 2022 | 307 | Main Document (3) Docket Text: MOTION to Strike Exhibits 37-41 and Related Testimony Introduced by Defendants during the June 28, 2022 Deposition Redirect of Dr. Tomislav Friscic - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Proposed Order, # (2) Rule 7.1.1. Certification)(Silver, Daniel) Modified on 7/12/2022 (nms). |
| Jul 11, 2022 | 307 | Text of Proposed Order (3) |
| Jul 11, 2022 | 307 | Rule 7.1.1. Certification (3) |
| Jul 7, 2022 | 306 | Stipulation (7) Docket Text: STIPULATION and Proposed Order to Extend Time, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2022 (nms). |
| Jul 1, 2022 | 304 | Main Document (9) Docket Text: MOTION to Preclude Expert Dr. Fintel from Offering Opinions on Topics Outside His Expertise - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) 7.1.1. Certification, # (2) Proposed Order)(Silver, Daniel) Modified on 7/5/2022 (nms). |
| Jul 1, 2022 | 304 | Rule 7.1.1. Certification (1) |
| Jul 1, 2022 | 304 | Text of Proposed Order (4) |
| Jul 1, 2022 | 305 | Main Document (4) Docket Text: DECLARATION of Shannon K. Clark, Esq. re [304] MOTION to Preclude Expert Dr. Fintel from Offering Opinions on Topics Outside His Expertise, by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits A-H)(Silver, Daniel) Modified on 7/5/2022 (nms). |
| Jul 1, 2022 | 305 | Exhibit A-H (222) |
| Jun 30, 2022 | N/A | Oral Argument (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Hearing on the Motion and Joinders to Strike held on 6/30/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: D. Gattuso, A. Poff, B. Palapura. The motion to strike expert reports (No. 20-md-2930, D.I. 622; No. 19-cv-1979, D.I. 456) was resolved as stated at the hearing. The transcript of the hearing shall serve as the order of the Court. (Court Reporter Deanna Warner.) Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA (lak) |
| Jun 28, 2022 | 303 | Main Document (5) Docket Text: REDACTED VERSION of [283] Letter, by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Exhibits 1 - 6)(Poff, Adam) Modified on 6/29/2022 (nms). |
| Jun 28, 2022 | 303 | Exhibit 1 - 6 (447) |
| Jun 27, 2022 | 302 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Tomislav Friscic, Ph.D. on June 28, 2022 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jun 23, 2022 | 300 | Redacted Document (8) Docket Text: REDACTED VERSION of [291] Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/23/2022 (nms). |
| Jun 23, 2022 | 301 | Redacted Document (30) Docket Text: REDACTED VERSION of [292] Declaration, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/23/2022 (nms). |
| Jun 22, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 298 in 19-cv-2053-RGA; D.I. 653 in 20-md-2930-RGA) STIPULATION and Proposed Order to Extend Redaction Deadline. Signed by Judge Richard G. Andrews on 6/22/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) |
| Jun 22, 2022 | 299 | Letter (1) Docket Text: Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding DRL stipulation of infringement and infringement trial. (Silver, Daniel) Modified on 6/23/2022 (nms). |
| Jun 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: The letter request (D.I. 279 in 19-cv-2053-RGA; D.I. 614 in 20-md-2930-RGA) to seal the transcript of 6/3/22, is DENIED without prejudice to filing a motion with the proposed redactions highlighted in yellow and evidentiary support for the sealing request. Ordered by Judge Richard G. Andrews on 6/21/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) |
| Jun 21, 2022 | 297 | Redacted Document (4) Docket Text: REDACTED VERSION of [287] Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/21/2022 (nms). |
| Jun 21, 2022 | 298 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION and Proposed Order to Extend Redaction Deadline - filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.. (Poff, Adam) Modified on 6/22/2022 (nms). |
| Jun 20, 2022 | 294 | Notice to Take Deposition (5) Docket Text: NOTICE to Take Deposition of Robin D. Rogers, Ph.D. on June 21, 2022 (remote) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Jun 17, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 646 in 20-md-2930-RGA; D.I. 196 in 20-cv-445-RGA; D.I. 468 in 19-cv-1979-RGA; D.I. 293 in 19-cv-2053-RGA; D.I. 174 in 19-cv-2021-RGA) STIPULATION and Proposed Order to Extend Time to submit a joint interim status report to July 7, 2022. Signed by Judge Richard G. Andrews on 6/17/2022. Associated Cases: 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA, 1:20-md-02930-RGA(nms) |
| Jun 17, 2022 | 293 | Stipulation to EXTEND Time (7) Docket Text: STIPULATION and Proposed Order to Extend Time for the parties to submit a joint interim status report to July 7, 2022 - filed by Mylan Pharmaceuticals Inc.. (Palapura, Bindu) Modified on 6/17/2022 (nms). |
| Jun 16, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A hearing on the Motion and Joinders to Strike (D.I. [623]; D.I. [627]; D.I. [631]) is now set for 6/30/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 6/16/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) |
| Jun 16, 2022 | 290 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Dr. Gregory Bell, Ph.D. on June 17, 2022 filed by Laurus Generics Inc., Laurus Labs Limited.(Poff, Adam) |
| Jun 15, 2022 | 286 | Notice to Take Deposition (8) Docket Text: NOTICE to Take Deposition of Alexander M. Klibanov, Ph.D. on June 16, 2022 (remote) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Jun 15, 2022 | 288 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Hatem Titi, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jun 14, 2022 | 284 | Letter (3) Docket Text: Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding the Courts June 3, 2022 Oral Order concerning patent expiration dates. (Silver, Daniel) Modified on 6/14/2022 (nms). |
| Jun 14, 2022 | 285 | Redacted Document (22) Docket Text: REDACTED VERSION of [274] Letter, by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc.. (Stamoulis, Stamatios) Modified on 6/15/2022 (nms). |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 282 in 19-cv-2053-RGA; D.I. 170 in 19-cv-2021-RGA; D.I. 459 in19-cv-1979-RGA; D.I. 628 in 20-md-2930-RGA; D.I. 188 in 20-cv-445-RGA)STIPULATION to Extend Time for the close of expert discovery to complete the depositions. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) |
| Jun 13, 2022 | N/A | Redaction Notice (0) Docket Text: REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI #[274]. (nms) |
| Jun 10, 2022 | 282 | Stipulation to EXTEND Time (7) Docket Text: STIPULATION and Proposed Order Extending Time for the close of expert discovery to complete the depositions - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 8, 2022 | 281 | Main Document (5) Docket Text: REDACTED VERSION of [267] Letter, by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc.. (Attachments: # (1) Exhibits 1-13)(Stamoulis, Stamatios) Modified on 6/8/2022 (nms). |
| Jun 8, 2022 | 281 | Exhibit 1-13 (193) |
| Jun 7, 2022 | 280 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Sur-reply Expert Report of Aeri Park, Ph.D., against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jun 6, 2022 | N/A | Redaction Notice (0) Docket Text: REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI #[267]. (nms) |
| Jun 6, 2022 | 277 | Notice (Other) (5) Docket Text: NOTICE of Defendants' Deposition of Adam J. Matzger, Ph.D. by Crystal Pharmaceutical (Suzhou) Co., Ltd. (Gattuso, Dominick) |
| Jun 6, 2022 | 278 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Dr. Jonathan W. Steed filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jun 6, 2022 | 279 | Letter (1) Docket Text: Letter to The Honorable Richard G. Andrews from Stamatios Stamoulis regarding sealing the transcript from the June 3, 2022 hearing. (Stamoulis, Stamatios) |
| Jun 3, 2022 | N/A | Motion Hearing (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Motion Hearing held on 6/3/2022, re 266 in 1:19-cv-02053-RGA, and 598 in 1:20-md-02930-RGA. Counsel for Plaintiff: A. Joyce. Counsel for Defendants: S. Stamoulis. The parties are to confer and submit a proposed order reflecting the rulings the Court made during the hearing. (Court Reporter Deanna Warner.) Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(lak) |
| Jun 3, 2022 | 275 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Sur-Sur-Reply Expert Report of Robin D. Rogers, Ph.D. Against Crystal Pharmaceutical (Suzhou) Co., Ltd., Mylan Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jun 3, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: It appears that the 30 month stay ends no earlier than July 7, 2023. (E.g., No. 19-1979, D.I. 3). Two of the asserted patents (the 659 and the 331) are said to expire on January 14, 2023. (Id.). The other two patents (the 938 and the 134) expire in 2026 and 2027. I think Novartis told me on April 21, 2022, that the first two patents, because of pediatric (or some other) exclusivity, if valid and infringed, would actually block any launch before July 14, 2023. The parties are to advise whether I have all this right. If it is right, I expect to prioritize the invalidity and infringement proceedings relating to the second set of patents. I do not see what sense it makes to invest a lot of time and effort trying cases relating to patents that may have no practical impact and at most would have limited practical impact. If one or more generics (which, by my count, are Biocon, Laurus, Teva, MacLeods, Zydus, Hetero, and DRL (Mylans trials being in West Virginia)) are successful against the later-expiring patents, there will be other ways to resolve the 659 and 331 claims. Ordered by Judge Richard G. Andrews on 6/3/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 2, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The pdf for D.I. [272] has been replaced with a corrected version per the filer's request. The caption on the filing has been amended. (nms) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 273 in 19-cv-2053-RGA; D.I. 608 in 20-md-2930-RGA) MOTION for Pro Hac Vice Appearance of Attorney Jacob C. Britz, filed by Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited. Signed by Judge Richard G. Andrews on 6/2/2022. Associated Cases: 1:19-cv-02053-RGA, 1:20-md-02930-RGA(nms) |
| Jun 2, 2022 | 273 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jacob C. Britz - filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.. (Poff, Adam) |
| Jun 1, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The Notice of Service (D.I. 602 in 20md2930-RGA; D.I. 270 in 19cv2053) filed on 5/31/2022, has been removed. The filing contained errors in the caption. Counsel shall refile the Notice of Service and reflect "RGA" after the case numbers. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) Modified on 6/1/2022 (nms). |
| Jun 1, 2022 | 270 | Redacted Document (4) Docket Text: REDACTED VERSION of [262] Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/1/2022 (nms). |
| Jun 1, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A letter of no more than three (3) pages in response to the MOTION to Strike New Infringement Opinions from the Expert Report of Aeri Park, Ph.D (D.I. 599 in 20md2930-RGA; D.I. 267 in 19cv2053-RGA) is due by the COB on 6/2/2022. A hearing on the motion is set for 6/3/2022, at 11:30 AM before Judge Richard G. Andrews. The hearing will be held via Teams. A joint email with the email addresses for all those participating in the hearing is due to the Court's Case Manager by 3:00 PM on 6/2/2022. Ordered by Judge Richard G. Andrews on 6/1/2022. Associated Cases: 1:19-cv-02053-RGA, 1:20-md-02930-RGA(nms) |
| Jun 1, 2022 | 272 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Sur-Reply Expert Report of Mark Hollingsworth Regarding Noninfringement of U.S. Patent No. 8,877,938 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) (Main Document 272 replaced on 6/2/2022) (nms). |
| May 31, 2022 | 268 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Sur-Sur-Reply Expert Report of Adam J. Matzger, Ph.D. Against Crystal Pharmaceutical (Suzhou) Co., Ltd., Mylan Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 31, 2022 | 269 | Notice to Take Deposition (8) Docket Text: NOTICE to Take Deposition of Bernhardt L. Trout, Ph.D. on June 1, 2022 filed by Laurus Generics Inc., Laurus Labs Limited.(Poff, Adam) |
| May 27, 2022 | 266 | Motion to Strike (3) Docket Text: MOTION to Strike New Infringement Opinions from the Expert Report of Aeri Park, Ph.D. - filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Stamoulis, Stamatios) Modified on 5/31/2022 (nms). |
| May 26, 2022 | 265 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Dan Fintel, M.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 25, 2022 | 263 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Dr. Laird Forrest filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 23, 2022 | 261 | Letter (3) Docket Text: Letter to The Honorable Richard G. Andrews from Daniel M. Silver, Esq. regarding Infringement Trials. (Silver, Daniel) |
| May 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 260 in 19-cv-2053-RGA; 441 in 19-cv-1979-RGA; D.I. 583 in 20-md-2930-RGA) STIPULATION TO EXTEND TIME for the parties to submit a joint letter regarding the Crystal and Zydus infringement trial concerning U.S. Patent Nos. 8,101,659, 8,796,331, 8,877,938 and 9,388,134 to May 20, 2022. Signed by Judge Richard G. Andrews on 5/19/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02053-RGA(nms) |
| May 18, 2022 | 260 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a joint letter regarding the Crystal and Zydus infringement trial concerning U.S. Patent Nos. 8,101,659, 8,796,331, 8,877,938 and 9,388,134 to May 20, 2022 - filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.. (Poff, Adam) |
| May 17, 2022 | 258 | Redacted Document (3) Docket Text: REDACTED VERSION of [253] Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/17/2022 (nms). |
| May 17, 2022 | 259 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Ivan T. Hofmann filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 16, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The Notice of Service (D.I. 577 in 20md2930-RGA; D.I. 437 in 19cv199-RGA; D.I. 164 19cv2021-RGA; D.I. 258 in 19cv2053-RGA; D.I. 178 in 20cv445-RGA) filed on 5/13/2022, has been removed. The filing contained errors in the caption. Counsel shall refile the Notice of Service and reflect "RGA" after the case numbers. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) |
| May 12, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 436 in 19-cv-1979-RGA; D.I. 257 in 19-cv-2053-RGA: D.I. 576 in 20-md-2930-RGA) STIPULATION and Proposed Order to Extend Time to submit joint letter regarding the Crystal and Zydus infringement trial concerning U.S. Patent Nos. 8,101,659, 8,796,331, 8,877,938 and 9,388,134 to May 18, 2022. Signed by Judge Richard G. Andrews on 5/12/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02053-RGA(nms) |
| May 11, 2022 | 255 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Alexander M. Klibanov, Ph.D. on May 12, 2022 filed by Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| May 11, 2022 | 256 | Letter (2) Docket Text: Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding infringement trial as to Dr. Reddy's Laboratories. (Silver, Daniel) Modified on 5/12/2022 (nms). |
| May 11, 2022 | 257 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION and Proposed Order to Extend Time to submit joint letter regarding the Crystal and Zydus infringement trial concerning U.S. Patent Nos. 8,101,659, 8,796,331, 8,877,938 and 9,388,134 to May 18, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/12/2022 (nms). |
| May 4, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 563 in 20-md-2930-RGA; D.I. 252 in 19-cv-2053-RGA) STIPULATION and Proposed Order to Extend Time to submit a joint letter regarding the DRL infringement trial concerning U.S. Patent Nos. 8,101,659; 8,796,331; 8,877,938; and 9,388,134 to May 11, 2022. Signed by Judge Richard G. Andrews on 5/4/2022. Associated Cases: 1:19-cv-02053-RGA, 1:20-md-02930-RGA(nms) |
| May 4, 2022 | 252 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a joint letter regarding the DRL infringement trial concerning U.S. Patent Nos. 8,101,659; 8,796,331; 8,877,938; and 9,388,134 in accordance with the Courts oral order at the April 21, 2022 status conference to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 3, 2022 | 251 | Notice of Service (11) Docket Text: NOTICE OF SERVICE of Supplemental Sur-Reply Expert Report of Dr. Alexander M. Klibanov on the Validity of the '659 Patent filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| May 2, 2022 | 249 | Main Document (5) Docket Text: UNOPPOSED Motion to Change Name of Defendant Cadila Healthcare Limited to Zydus Lifesciences Limited - filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Text Proposed Order)(Poff, Adam) Modified on 5/2/2022 (nms). |
| May 2, 2022 | 249 | Text of Proposed Order (2) |
| May 2, 2022 | 250 | Order (2) Docket Text: ORDER Granting (D.I. 555 in 20-md-2930-RGA; D.I. 249 in 19-cv-2053-RGA) Unopposed Motion to Change Name of Defendant Cadila Healthcare Limited to Zydus Lifesciences Limited. Signed by Judge Richard G. Andrews on 5/2/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA(nms) |
| Apr 28, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 246 in 19-cv-2053-RGA; D.I. 550 in 20-md-2930-RGA) STIPULATION and Proposed Order to Extend Time to submit a joint letter regarding the Zydus infringement trial concerning U.S. Patent Nos. 8,101,659, 8,796,331, 8,877,938 and 9,388,134 to May 11, 2022. Signed by Judge Richard G. Andrews on 4/28/2022. Associated Cases: 1:19-cv-02053-RGA, 1:20-md-02930-RGA(nms) |
| Apr 28, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 247 in 19-cv-2053-RGA; D.I. 552 in 20-md-2930-RGA) STIPULATION and Proposed Order to Extend Time to submit a joint letter regarding the DRL infringement trial concerning U.S. Patent Nos. 8,101,659; 8,796,331; 8,877,938; and 9,388,134 to and including May 4, 2022. Signed by Judge Richard G. Andrews on 4/28/2022. Associated Cases: 1:19-cv-02053-RGA, 1:20-md-02930-RGA(nms) |
| Apr 28, 2022 | 248 | Letter (2) Docket Text: Letter to The Honorable Richard G. Andrews from Adam W. Poff regarding Defendants' request for trial date on infringement of the '659 and '331 patents. (Poff, Adam) |
| Apr 27, 2022 | 246 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME the deadline to submit a joint letter regarding the Zydus infringement trial concerning U.S. Patent Nos. 8,101,659, 8,796,331, 8,877,938 and 9,388,134 to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 27, 2022 | 247 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a joint letter regarding the DRL infringement trial concerning U.S. Patent Nos. 8,101,659; 8,796,331; 8,877,938; and 9,388,134 in accordance with the Courts oral order at the April 21, 2022 status conference to May 4, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 4/28/2022 (nms). |
| Apr 21, 2022 | N/A | Status Conference (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Status/scheduling Conference held on 4/21/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: D. Gattuso, K. Keller, J. Miller, D. Bortz, M. Haney, C. Hitch, A. Poff, J. Seaman, S. Stamoulis. The parties shall submit proposed scheduled two weeks from today. (Court Reporter Heather Triozzi.) Associated Cases: 1:20-md-02930-RGA et al.(lak) |
| Apr 20, 2022 | 244 | Notice of Service (12) Docket Text: NOTICE OF SERVICE of (1) Sur-Reply Expert Report of Francis G. Spinale, MD, PH.D. regarding Validity and (2) Sur-Reply Report of Gregory K. Bell, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 20, 2022 | 245 | Notice of Service (11) Docket Text: NOTICE OF SERVICE of Sur-Reply Expert Report of Dr. Alexander M. Klibanov on the Validity of the 659 and 331 Patents filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 11, 2022 | N/A | Case No Longer Referred to Mediation (0) Docket Text: CASE NO LONGER REFERRED to Magistrate Judge Burke for the purpose of exploring ADR. Please see the Court's Standing Order No. 2022-2 dated March 14, 2022. (dlb) |
| Apr 11, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: Due to a scheduling conflict the Status/Scheduling Conference scheduled for 4/20/2022, is CANCELED. The Status/Scheduling Conference is now rescheduled for 4/21/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 4/11/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Apr 8, 2022 | 240 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Reply Expert Report of Aeri Park, Ph.D., Against Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 8, 2022 | 241 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of (1) Reply Expert Report of Adam J. Matzger, Ph.D. Against Crystal Pharmaceutical (Suzhou) Co., Ltd., Mylan Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. and (2) Reply Expert Report of Robin D. Rogers, Ph.D. Against Crystal Pharmaceutical (Suzhou) Co., Ltd., Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd., and Mylan Pharmaceuticals, Inc. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 8, 2022 | 242 | Redacted Document (4) Docket Text: REDACTED VERSION of [233] Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/11/2022 (nms). |
| Apr 4, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Status/Scheduling Conference is now set for 4/20/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 4/4/2022. Associated Cases: 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00074-RGA, 1:20-cv-00415-RGA(nms) |
| Apr 1, 2022 | 235 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Reply Expert Report of Dr. Jonathan W. Steed filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) |
| Apr 1, 2022 | 236 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of the Reply Expert Report of Dan Fintel, M.D., on the Invalidity of the '659 and '331 Patents filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc..(Ormerod, Eve) |
| Apr 1, 2022 | 237 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Reply Expert Report of Dr. Alexander M. Klibanov on Infringement by Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 1, 2022 | 238 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Reply Expert Report of Dr. Laird Forrest Regarding Invalidity of U.S. Patent Nos. 8,101,659 and 8,796,331 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Mar 28, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 169 in 20-cv-445-RGA; D.I. 520 in 20-md-2930-RGA: D.I. 410 in 19-cv-1979-RGA; D.I. 232 in 19-cv-2053-RGA) STIPULATION TO EXTEND TIME to serve reply expert reports concerning infringement to April 7, 2022. Signed by Judge Richard G. Andrews on 3/28/2022. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02053-RGA, 1:20-cv-00445-RGA(nms) |
| Mar 25, 2022 | 232 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION and Proposed Order to Extend Time to serve reply expert reports concerning infringement to April 7, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/28/2022 (nms). |
| Mar 21, 2022 | 231 | Status Report (17) Docket Text: JOINT Status Report, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 3/22/2022 (nms). |
| Mar 16, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: The parties to the MDL and its member cases are to file a joint status report no later than three (3) days from the date of this Order. Specifically the parties should address (1) scheduled deadlines and events currently in place, (2) matters that are outstanding and need Court attention, and (3) for the cases related to the MDL but not member cases of the MDL, what the relationship is, including in particular what overlap (for example, the same patents, different patents but the same patent family, the same branded products, the same generic products) the related cases have with the member cases. Ordered by Judge Richard G. Andrews on 3/16/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Mar 15, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, 1:20-cv-00074-RGA and 1:20-cv-00445-RGA (rjb) |
| Mar 15, 2022 | 229 | Order (1) Docket Text: ORDER in MDL No. 2930 Reassigning Litigation to Judge Richard G. Andrews. Signed by Karen K. Caldwell, Chair on 3/15/22. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Feb 17, 2022 | 228 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Responsive Expert Report of Mark Hollingsworth Regarding Noninfringement of U.S. Patent No. 8,877,938 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Feb 11, 2022 | 225 | Notice of Service (17) Docket Text: NOTICE OF SERVICE of (1) Responsive Expert Report of Francis G. Spinale, MD, PHD Regarding Validity of the 659 and 331 Patents; (2) Responsive Expert Report of Dr. Alexander M. Klibanov on the Validity of the 659 and 331 Patents; and (3) Expert Report of Gregory K. Bell, PH.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Feb 11, 2022 | 226 | Notice of Service (9) Docket Text: NOTICE OF SERVICE of Responsive Expert Report of Bernhardt L. Trout, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Feb 11, 2022 | 227 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Responsive Expert Report of Mark D. Hollingsworth Regarding Noninfringement of U.S. Patent No. 8,101,659 filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) |
| Feb 8, 2022 | 224 | Redacted Document (4) Docket Text: REDACTED VERSION of (223 in 1:19-cv-02053-LPS, 479 in 1:20-md-02930-LPS) Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Feb 3, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (223 in 1:19-cv-02053-LPS, 479 in 1:20-md-02930-LPS) [SEALED] STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against MSN and MSN's Counterclaims Against the '938 and '134 Patents. Signed by Judge Leonard P. Stark on 2/2/22. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Jan 31, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (222 in 1:19-cv-02053-LPS, 477 in 1:20-md-02930-LPS) STIPULATION TO EXTEND TIME for certain case deadlines related to expert discovery to various dates filed by Dr. Reddys Laboratories, Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd. Signed by Judge Leonard P. Stark on 1/31/22. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Jan 26, 2022 | 222 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for certain case deadlines related to expert discovery to various dates - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc.. (Stamoulis, Stamatios) |
| Dec 27, 2021 | 221 | Transcript (25) Docket Text: Official Transcript of Telephone Conference held on December 10, 2021 before Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/18/2022. Redacted Transcript Deadline set for 1/27/2022. Release of Transcript Restriction set for 3/28/2022. (bpg) |
| Dec 16, 2021 | 220 | Redacted Document (6) Docket Text: REDACTED VERSION of (214 in 1:19-cv-02053-LPS, 455 in 1:20-md-02930-LPS) Letter, by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd.. (Poff, Adam) |
| Dec 15, 2021 | 216 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Opening Expert Report of Dan Fintel, M.D., on the Invalidity of the '659 and '331 Patents filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc..(Ormerod, Eve) |
| Dec 15, 2021 | 217 | Redacted Document (8) Docket Text: REDACTED VERSION of (213 in 1:19-cv-02053-LPS, 454 in 1:20-md-02930-LPS) Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Dec 15, 2021 | 218 | Notice of Service (18) Docket Text: NOTICE OF SERVICE of Opening Expert Reports filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Dec 15, 2021 | 219 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Opening Expert Report of Laird Forrest Regarding Invalidity of U.S. Patent Nos. 8,101,659 and 8,796,331 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Dec 14, 2021 | 215 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Expert Report of Dr. Jonathan W. Steed filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) |
| Dec 10, 2021 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 12/10/2021. (Court Reporter B. Gaffigan.) Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Dec 6, 2021 | N/A | Order Setting Teleconference (0) Docket Text: ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for December 10, 2021 at 4:45 p.m. The parties and any interested members of the public can access the teleconference by dialing 877-336-1829 and using the access code 1408971. IT IS FURTHER ORDERED that not later than December 8, 2021 any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than December 9, 2021, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 12/6/2021. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Nov 30, 2021 | 210 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling a Discovery Teleconference. (Silver, Daniel) |
| Nov 30, 2021 | 211 | Notice of Appearance (3) Docket Text: NOTICE of Appearance by Richard Charles Weinblatt on behalf of MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. (Weinblatt, Richard) |
| Nov 24, 2021 | 206 | Redacted Document (3) Docket Text: REDACTED VERSION of (200 in 1:19-cv-02053-LPS, 413 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Nov 24, 2021 | 207 | Redacted Document (3) Docket Text: REDACTED VERSION of (414 in 1:20-md-02930-LPS, 201 in 1:19-cv-02053-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Nov 24, 2021 | 208 | Redacted Document (4) Docket Text: REDACTED VERSION of (202 in 1:19-cv-02053-LPS, 416 in 1:20-md-02930-LPS) Stipulation of Dismissal by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Nov 24, 2021 | 209 | Redacted Document (6) Docket Text: REDACTED VERSION of (203 in 1:19-cv-02053-LPS, 417 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Nov 22, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (202 in 1:19-cv-02053-LPS, 416 in 1:20-md-02930-LPS) STIPULATION of Dismissal of Novartis's '938 and '134 Patent Claims Against Hetero and Hetero's Counterclaims Against the '938 and '134 Patents filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/22/21. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Nov 22, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (203 in 1:19-cv-02053-LPS, 417 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Staying Litigation with Respect to Novugen Pharma (Malaysia) SDN, BHD filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/22/21. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Nov 18, 2021 | 205 | Redacted Document (4) Docket Text: REDACTED VERSION of (199 in 1:19-cv-02053-LPS, 410 in 1:20-md-02930-LPS) Stipulation by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 16, 2021 | 204 | Redacted Document (17) Docket Text: REDACTED VERSION of (196 in 1:19-cv-02053-LPS, 114 in 1:20-cv-00415-LPS, 339 in 1:19-cv-01979-LPS, 132 in 1:19-cv-02021-LPS, 35 in 1:21-cv-00229-LPS, 106 in 1:20-cv-00074-LPS, 157 in 1:20-cv-00445-LPS, 407 in 1:20-md-02930-LPS) Status Report by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 12, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (199 in 1:19-cv-02053-LPS, 410 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Dismissing Novartis's '938 and '134 Patent Claims Against Novugen filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/12/21. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Nov 9, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Whitney M. Howard for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-LPS et al.(srs) |
| Nov 9, 2021 | 197 | Notice (Other) (3) Docket Text: NOTICE of Withdrawal of Beth A. Swadley by Novugen Pharma (Malaysia) Sdn. Bhd. (Poff, Adam) |
| Nov 9, 2021 | 198 | Notice (Other) (4) Docket Text: NOTICE of Withdrawal of Beth A. Swadley, Esquire by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc. (Poff, Adam) |
| Nov 8, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (156 in 1:20-cv-00445-LPS, 131 in 1:19-cv-02021-LPS, 105 in 1:20-cv-00074-LPS, 195 in 1:19-cv-02053-LPS, 337 in 1:19-cv-01979-LPS, 405 in 1:20-md-02930-LPS, 113 in 1:20-cv-00415-LPS) MOTION for Pro Hac Vice Appearance of Attorney Whitney Meier Howard filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/8/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Nov 5, 2021 | 195 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Whitney Meier Howard - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certification for Whitney Meier Howard)(Silver, Daniel) |
| Nov 5, 2021 | 195 | Certification for Whitney Meier Howard (1) |
| Nov 4, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (336 in 1:19-cv-01979-LPS, 104 in 1:20-cv-00074-LPS, 404 in 1:20-md-02930-LPS, 194 in 1:19-cv-02053-LPS, 130 in 1:19-cv-02021-LPS, 155 in 1:20-cv-00445-LPS, 112 in 1:20-cv-00415-LPS, 34 in 1:21-cv-00229-LPS) STIPULATION TO EXTEND TIME the Deadline for the Submissionof the Joint Status Report to November 8, 2021 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/4/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Nov 3, 2021 | 194 | Stipulation to EXTEND Time (12) Docket Text: STIPULATION TO EXTEND TIME the Deadline for the Submissionof the Joint Status Report to November 8, 2021 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 25, 2021 | 193 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Hetero's Objections and Responses to Plaintiff's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Hetero USA Inc., Hetero Labs Limited and Hetero Labs Limited Unit III filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,.(Ormerod, Eve) |
| Oct 21, 2021 | 191 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of 1) Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Fourth Set of Requests for Production (No. 87); 2) Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Third Set of Interrogatories (No. 6); 3) Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss First Set of Requests for Admissions (Nos. 1-27); and 4) Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Response to Novartiss Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth) |
| Oct 21, 2021 | 192 | Notice of Service (18) Docket Text: NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Requests for Admission (Nos. 1-18); (2) Novartis's Objections and Responses to Defendant Teva's First Set of Requests for Admissions (Nos. 1-9); (3) Novartis's Objections and Responses to Defendant Teva's First Set of Individual Interrogatories (Nos. 1-9); and (4) Novartis's Objections and Responses to Defendant Zydus's First Set of Requests for Admissions (Nos. 1-8) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Oct 20, 2021 | 184 | Notice of Service (14) Docket Text: NOTICE OF SERVICE of Novartis's Second Supplemental Response to Defendants' Interrogatory No. 3 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Oct 20, 2021 | 185 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Michael Motto on October 22, 2021 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Oct 20, 2021 | 186 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Hetero's Objections and Responses to Plaintiff's Third Set of Interrogatories to Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III (No. 6), 2) Hetero's Objections and Responses to Novartis's Fourth Set of Requests to Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III for the Production of Documents and Things (No. 75), and 3) Hetero's Objections and Responses to Novartis's First Set of Requests for Admission to Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III (Nos. 1-27) filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,.(Ormerod, Eve) |
| Oct 20, 2021 | 187 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Third Set of Interrogatories (No. 6); 2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Fourth Set of Requests for The Production of Documents and Things (Nos. 75-76); 3) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's First Set of Requests for Admission (Nos. 1-50); and 4) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Second Supplemental Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Oct 20, 2021 | 188 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Objections and Responses to Novartiss Third Set of Interrogatories to DRL (No. 6), (2) MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Plaintiffs Fifth Set of Requests for the Production of Documents and Things, and (3) MSN Pharmaceuticals, Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Plaintiffs First Set of Requests for Admissions filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) |
| Oct 20, 2021 | 189 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendants Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd. Amended Initial Disclosures Pursuant to Fed. R. Civ. P. 16(a)(1), (2) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s Second Supplemental Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5), (3) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss Third Set of Interrogatories to DRL (No. 6), (4) Dr. Reddys Laboratories, Inc.s and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss Fourth Set of Requests to Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd. for the Production of Documents and Things (No. 75), and (5) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd. Objections and Responses to Novartiss First Set of Requests for Admission (Nos. 1-50) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Oct 20, 2021 | 190 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Objections and Responses to Novartiss Second Set of Common Interrogatories to Defendants (No. 2) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Oct 19, 2021 | 183 | Notice of Service (19) Docket Text: NOTICE OF SERVICE of Discovery Responses filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Oct 18, 2021 | 182 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Plaintiffs Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) |
| Oct 15, 2021 | 181 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of DRLs Objections and Responses to Novartiss Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd. filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Oct 14, 2021 | 180 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Oct 8, 2021 | 179 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of MSN Pharmaceuticals Inc.s, MSN Laboratories Private Limiteds and MSN Life Sciences Private Limiteds Supplemental Response to Plaintiffs Second Set of Interrogatories (Nos. 3-5) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) |
| Oct 1, 2021 | 178 | Notice to Take Deposition (8) Docket Text: NOTICE to Take Deposition of Michael Exton on October 5, 2021 filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) |
| Sep 21, 2021 | 176 | Notice of Service (21) Docket Text: NOTICE OF SERVICE of (1) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Defendants, (2) Novartis's Third Set Of Interrogatories To Defendants, (3) Novartis's Fourth Set of Requests to Defendants for the Production of Documents and Things, (4) Novartis's First Set Of Requests For Admissions To Defendants, and (5) Novartis's Second Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Sep 21, 2021 | 177 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus's First Set of Individual Requests for Admission (Nos. 1-10) to Plaintiff Novartis Pharmaceuticals Corporation filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Sep 20, 2021 | 174 | Notice of Service (19) Docket Text: NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' Notice of Deposition to Plaintiff Pursuant to Fed. R. Civ. P. 30(b)(6) and (2) Plaintiff's Second Supplemental Infringement Contentions Against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Sep 20, 2021 | 175 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Zydus's First Set of Individual Requests for the Production of Documents and Things (Nos. 1-2) to Plaintiff Novartis Pharmaceuticals Corporation; and 2) Zydus's First Set of Individual Interrogatories (Nos. 1-4) to Plaintiff Novartis Pharmaceuticals Corporation filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Sep 17, 2021 | 173 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendants' Supplemental Joint Invalidity Contentions filed by Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Dorsney, Kenneth) |
| Sep 16, 2021 | 172 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s Second Supplemental Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Sep 15, 2021 | 163 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Yugang Liu on on a mutually agreed-upon date filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 164 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Sven Erik Godtfredsen on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 165 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Paul Sutton on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 166 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Bin Hu on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 167 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Lili Feng on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 168 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Mahavir Prashad on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 169 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Michael J. Girgis on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 170 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Piotr Karpinski on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 15, 2021 | 171 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Thomas J. Blacklock on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 14, 2021 | 162 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendant Crystal Pharma's Second Set of Individual Interrogatories (No. 4) to Plaintiff Novartis Pharmaceuticals Corporation filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 13, 2021 | 161 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s First Set of Individual Interrogatories (Nos. 1-4); and (2) Novartis's Objections and Responses to Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s First Set of Individual Requests for the Production of Documents and Things (Nos. 1-6) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Sep 8, 2021 | 159 | Notice to Take Deposition (19) Docket Text: NOTICE to Take Deposition of NOVARTIS PHARMACEUTICALS CORPORATION on a mutually agreed upon date and time filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 8, 2021 | 160 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Randy Lee Webb on September 24, 2021 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Aug 31, 2021 | 158 | Notice of Service (20) Docket Text: NOTICE OF SERVICE of (1) Plaintiff's First Supplemental Infringement Contentions Against Defendants, and (2) Novartis's First Supplemental Objections and Responses to Defendant's First Set of Individual Interrogatories (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Aug 27, 2021 | 157 | Notice of Service (15) Docket Text: NOTICE OF SERVICE of Novartis's Second Supplemental Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-7) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 12, 2021 | 156 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s First Set of Individual Requests for the Production of Documents and Things (Nos. 1-6) and (2) Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s First Set of Individual Interrogatories (Nos. 1-4) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Jul 14, 2021 | 155 | Answer to Counterclaim (23) Docket Text: ANSWER to [150] Answer to Amended Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 8, 2021 | 153 | Answer to Counterclaim (18) Docket Text: ANSWER to [147] Answer to Amended Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 8, 2021 | 154 | Answer to Counterclaim (27) Docket Text: ANSWER to [148] Answer to Amended Complaint,, Counterclaim, by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jun 23, 2021 | 150 | Answer to Amended Complaint (30) Docket Text: ANSWER to Amended Complaint, re: [145] Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) |
| Jun 23, 2021 | 151 | Answer to Amended Complaint (30) Docket Text: ANSWER to Amended Complaint, re: [145] Amended Complaint, with Affirmative Defenses by Novugen Pharma (Malaysia) Sdn. Bhd..(Poff, Adam) |
| Jun 23, 2021 | 152 | Answer to Amended Complaint (30) Docket Text: ANSWER to Amended Complaint, re: [145] Amended Complaint, by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Poff, Adam) |
| Jun 18, 2021 | 149 | Transcript (115) Docket Text: Official Transcript of Claim Construction Hearing held on June 8, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 7/9/2021. Redacted Transcript Deadline set for 7/19/2021. Release of Transcript Restriction set for 9/16/2021. (bpg) |
| Jun 17, 2021 | 147 | Answer to Amended Complaint (30) Docket Text: ANSWER to Amended Complaint, re: [145] Amended Complaint, and Hetero USA, Inc.'s, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Hetero Labs Limited, Hetero USA Inc., Hetero Labs Limited Unit III.(Ormerod, Eve) |
| Jun 17, 2021 | 148 | Answer to Amended Complaint (30) Docket Text: ANSWER to Amended Complaint, re: [145] Amended Complaint, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., MSN Laboratories Private Limited.(Stamoulis, Stamatios) |
| Jun 14, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Ronald M. Daignault, Richard Juang for MSN Laboratories Private Limited,for MSN Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (Associated Cases: 1:20-md-02930-LPS, 1:19-cv-02053-LPS) (myr) |
| Jun 11, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (146 in 1:19-cv-02053-LPS, 271 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Ronald M. Daignault and Richard Juang filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 6/11/21. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-02053-LPS (ntl) |
| Jun 10, 2021 | 146 | Motion for Leave to Appear Pro Hac Vice (6) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Ronald M. Daignault and Richard Juang - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Stamoulis, Stamatios) |
| Jun 9, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (250 in 1:20-md-02930-LPS, 85 in 1:19-cv-02021-LPS, 66 in 1:20-cv-00415-LPS, 236 in 1:19-cv-01979-LPS, 13 in 1:21-cv-00229-LPS, 115 in 1:20-cv-00445-LPS, 63 in 1:20-cv-00074-LPS, 133 in 1:19-cv-02053-LPS) STIPULATION and [Proposed] Order Regarding Plaintiff Novartis Pharmaceuticals Corporation's Amended Complaints. Signed by Judge Leonard P. Stark on 6/9/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Jun 9, 2021 | 145 | Main Document (62) Docket Text: AMENDED COMPLAINT against Cadila Healthcare Ltd., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Novugen Pharma (Malaysia) Sdn. Bhd., Zydus Pharmaceuticals (USA) Inc.- filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-D)(Silver, Daniel) |
| Jun 9, 2021 | 145 | Exhibit A-D (67) |
| Jun 8, 2021 | N/A | Markman Hearing (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Markman Hearing (by remote video) held on 6/8/2021. (Court Reporter B. Gaffigan.) Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Jun 8, 2021 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Magistrate Judge Christopher J. Burke for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf (Taylor, Daniel) |
| Jun 8, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER: If during the history of this case, Plaintiff(s) and Defendant(s) jointly wish to schedule a form of alternative dispute resolution ("ADR"), such as mediation, with Judge Burke, they should contact chambers by e-mail at Deborah_Benyo@ded.uscourts.gov or by phone. Additionally, if either side wishes to speak ex parte with Judge Burke regarding ADR matters, they may contact chambers via e-mail or by phone to arrange a time for a call. Ordered by Judge Christopher J. Burke on 6/8/2021. Associated Cases: 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00074-LPS, 1:20-cv-00415-LPS, 1:20-cv-00445-LPS(dlb) |
| Jun 7, 2021 | 143 | Main Document (3) Docket Text: Letter to Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Dispute Letter - re (261 in 1:20-md-02930-LPS) Order,,. (Attachments: # (1) Exhibit A)(Silver, Daniel) |
| Jun 7, 2021 | 143 | Exhibit A (38) |
| Jun 3, 2021 | N/A | Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that the Markman hearing on June 8, 2021 at 10:00 a.m. is available to the public using the following dial-in for audio access: +1 646 828 7666 US -- Meeting ID: 161 238 3790 -- Passcode: 824345 -- One Tap Mobile Public Dial-In Number: +16468287666,,1612383790#,,,,*824345# US. Audio reproduction of the proceeding is strictly prohibited. ORDERED by Judge Leonard P. Stark on 6/3/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| May 25, 2021 | 141 | Main Document (2) Docket Text: Letter to Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Claim Construction Hearing. (Attachments: # (1) Exhibit 58)(Silver, Daniel) |
| May 25, 2021 | 141 | Exhibit 58 (13) |
| May 24, 2021 | N/A | Order (0) Docket Text: ORAL ORDER: Having reviewed the parties' letter concerning the claim construction hearing scheduled for June 8 at 10:00 a.m. (C.A. No. 20-md-2930 D.I. 256), IT IS HEREBY ORDERED that each side will be allocated 75 minutes for its presentation. The hearing will be conducted by videoconference technology. Defendants shall submit access information for the Court, including access information for any interested member of the public, in advance of the hearing. The parties may present argument in the order they propose in the letter. IT IS FURTHER ORDERED that each party shall submit any slides or other materials to be referenced at the hearing by no later than June 7 at 4:00 p.m. ORDERED by Judge Leonard P. Stark on 5/24/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| May 21, 2021 | 136 | Joint Claim Construction Brief (30) Docket Text: JOINT CLAIM CONSTRUCTION BRIEF filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 21, 2021 | 137 | Main Document (16) Docket Text: APPENDIX re (14 in 1:21-cv-00229-LPS) Joint Claim Construction Brief, (88 in 1:19-cv-02021-LPS) Joint Claim Construction Brief, (69 in 1:20-cv-00415-LPS) Joint Claim Construction Brief, (118 in 1:20-cv-00445-LPS) Joint Claim Construction Brief, (136 in 1:19-cv-02053-LPS) Joint Claim Construction Brief, (253 in 1:20-md-02930-LPS) Joint Claim Construction Brief, (239 in 1:19-cv-01979-LPS) Joint Claim Construction Brief, (66 in 1:20-cv-00074-LPS) Joint Claim Construction Brief (Volume 1 -- Exhibits A-D) by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-D)(Silver, Daniel) |
| May 21, 2021 | 137 | Exhibit A-D (431) |
| May 21, 2021 | 138 | Main Document (16) Docket Text: APPENDIX re (14 in 1:21-cv-00229-LPS) Joint Claim Construction Brief, (88 in 1:19-cv-02021-LPS) Joint Claim Construction Brief, (69 in 1:20-cv-00415-LPS) Joint Claim Construction Brief, (118 in 1:20-cv-00445-LPS) Joint Claim Construction Brief, (136 in 1:19-cv-02053-LPS) Joint Claim Construction Brief, (253 in 1:20-md-02930-LPS) Joint Claim Construction Brief, (239 in 1:19-cv-01979-LPS) Joint Claim Construction Brief, (66 in 1:20-cv-00074-LPS) Joint Claim Construction Brief (Volume 2 -- Exhibits 1-57) by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1-29, # (2) Exhibit 35-43, # (3) Exhibit 44, # (4) Exhibit 45-57)(Silver, Daniel) |
| May 21, 2021 | 138 | Exhibit 1-29 (200) |
| May 21, 2021 | 138 | Exhibit 35-43 (83) |
| May 21, 2021 | 138 | Exhibit 44 (54) |
| May 21, 2021 | 138 | Exhibit 45-57 (180) |
| May 21, 2021 | 139 | Letter (2) Docket Text: Letter to The Honorable Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Claim Construction Hearing. (Silver, Daniel) |
| May 20, 2021 | 135 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendants Objection to Plaintiffs Notice of Deposition of Raymond Butcher, Ph.D., Pursuant to Fed. R. Civ. P. 30(b)(1) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| May 19, 2021 | 134 | Statement (6) Docket Text: STATEMENT re (241 in 1:20-md-02930-LPS, 228 in 1:19-cv-01979-LPS) Letter Novartis's Comments on Defendants' Technology Tutorial by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 18, 2021 | 132 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (i) Defendants Joint Sur-Reply Claim Construction Brief [with Exhibit 57]; and, (ii) the Declaration of Raymond Butcher, PhD. filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) |
| May 18, 2021 | 133 | Main Document (13) Docket Text: STIPULATION and [Proposed] Order Regarding Plaintiff Novartis Pharmaceuticals Corporation's Amended Complaints by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-N)(Silver, Daniel) |
| May 18, 2021 | 133 | Exhibit A-N (614) |
| May 17, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (82 in 1:19-cv-02021-LPS, 60 in 1:20-cv-00074-LPS, 112 in 1:20-cv-00445-LPS, 247 in 1:20-md-02930-LPS, 233 in 1:19-cv-01979-LPS, 63 in 1:20-cv-00415-LPS, 12 in 1:21-cv-00229-LPS, 130 in 1:19-cv-02053-LPS) STIPULATION TO EXTEND TIME for Paintiff to Amend or Supplement Pleadings to May 18, 2021 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 5/17/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| May 17, 2021 | N/A | Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that: (1) the claim construction hearing will be held remotely; (2) the claim construction hearing is RESCHEDULED to June 8, 2021 at 10:00 a.m.; and (3) the parties shall advise the Court, simultaneously with filing their joint claim construction brief, of the number of hours they request for the hearing and whether they prefer to proceed by video or telephone conference. ORDERED by Judge Leonard P. Stark on 5/17/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| May 14, 2021 | 130 | Stipulation to EXTEND Time (13) Docket Text: STIPULATION TO EXTEND TIME Deadline for Paintiff to Amend or Supplement Pleadings to May 18, 2021 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 11, 2021 | 129 | Notice (Other) (5) Docket Text: NOTICE of Deposition of Raymond Butcher, Ph.D., Pursuant to Fed. R. Civ. P. 30(b)(1) by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| May 5, 2021 | 128 | Letter (1) Docket Text: Letter to The Honorable Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiff's Technology Tutorial. (Silver, Daniel) |
| Apr 29, 2021 | 127 | Notice of Service (16) Docket Text: NOTICE OF SERVICE of (1) Novartis's Reply Claim Construction Brief, (2) Declaration of Laura K. Fishwick, Esq., and (3) Reply Declaration of Alexander M. Klibanov, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 27, 2021 | 126 | Notice (Other) (2) Docket Text: NOTICE of Change of Address by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Torrent Pharmaceuticals Ltd., Hetero USA Inc. (Ormerod, Eve) |
| Apr 21, 2021 | 125 | Notice of Service (15) Docket Text: NOTICE OF SERVICE of Novartis's Objections to Defendants' Notice of Deposition of Alexander M. Klibanov, Ph.D., Pursuant to Fed. R. Civ. P. 30(b)(1) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Apr 14, 2021 | 124 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of documents in response to Request for Productions identified by bates range DRL-SV00037475 DRL-SV00166523 filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Mar 30, 2021 | 123 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Alexander M. Klibanov, Ph.D., on May 5, 2021 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Mar 16, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (223 in 1:20-md-02930-LPS, 52 in 1:20-cv-00074-LPS, 74 in 1:19-cv-02021-LPS, 103 in 1:20-cv-00445-LPS, 215 in 1:19-cv-01979-LPS, 122 in 1:19-cv-02053-LPS, 55 in 1:20-cv-00415-LPS) STIPULATION and [Proposed] Order Extending Deadline to Amend the Pleadings; (51 in 1:20-cv-00074-LPS, 121 in 1:19-cv-02053-LPS, 213 in 1:19-cv-01979-LPS, 54 in 1:20-cv-00415-LPS, 73 in 1:19-cv-02021-LPS, 102 in 1:20-cv-00445-LPS, 221 in 1:20-md-02930-LPS) STIPULATION and [Proposed] Order Extending Time to Meet and Confer Regarding Depositions. Signed by Judge Leonard P. Stark on 3/15/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Mar 12, 2021 | 122 | Stipulation (12) Docket Text: STIPULATION and [Proposed] Order Extending Deadline to Amend the Pleadings re (45 in 1:19-cv-02021-LPS, 33 in 1:20-cv-00415-LPS, 102 in 1:20-md-02930-LPS, 29 in 1:20-cv-00074-LPS, 78 in 1:19-cv-02053-LPS, 137 in 1:19-cv-01979-LPS, 74 in 1:20-cv-00445-LPS) Scheduling Order,, by Mylan Pharmaceuticals Inc.. (Palapura, Bindu) |
| Mar 11, 2021 | 121 | Stipulation (12) Docket Text: STIPULATION and [Proposed] Order Extending Time to Meet and Confer Regarding Depositions by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 4, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (213 in 1:20-md-02930-LPS, 206 in 1:19-cv-01979-LPS, 52 in 1:20-cv-00415-LPS, 99 in 1:20-cv-00445-LPS, 71 in 1:19-cv-02021-LPS, 119 in 1:19-cv-02053-LPS, 49 in 1:20-cv-00074-LPS) STIPULATION TO EXTEND TIME for the substantial completion of document production to April 14, 2021 filed by Biocon Limited, Biocon Pharma, Inc., Alkem Laboratories Ltd., Biocon Pharma Limited, Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. Signed by Judge Leonard P. Stark on 3/3/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Mar 4, 2021 | 120 | Notice of Service (14) Docket Text: NOTICE OF SERVICE of (1) Novartiss Opening Claim Construction Brief and (2) Declaration of Alexander M. Klibanov filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 1, 2021 | 119 | Stipulation to EXTEND Time (12) Docket Text: STIPULATION TO EXTEND TIME for the substantial completion of document production to April 14, 2021 - filed by Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Dorsney, Kenneth) |
| Feb 17, 2021 | 117 | Claim Construction Chart (23) Docket Text: CLAIM Construction Chart by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 17, 2021 | 118 | Main Document (15) Docket Text: APPENDIX re (96 in 1:20-cv-00445-LPS, 117 in 1:19-cv-02053-LPS, 199 in 1:19-cv-01979-LPS, 69 in 1:19-cv-02021-LPS, 50 in 1:20-cv-00415-LPS, 205 in 1:20-md-02930-LPS, 47 in 1:20-cv-00074-LPS) Claim Construction Chart by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1-17, # (2) Exhibit 18-25, # (3) Exhibit 26-36)(Silver, Daniel) |
| Feb 17, 2021 | 118 | Exhibit 1-17 (163) |
| Feb 17, 2021 | 118 | Exhibit 18-25 (146) |
| Feb 17, 2021 | 118 | Exhibit 26-36 (92) |
| Feb 16, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (68 in 1:19-cv-02021-LPS, 196 in 1:19-cv-01979-LPS, 115 in 1:19-cv-02053-LPS, 201 in 1:20-md-02930-LPS, 49 in 1:20-cv-00415-LPS, 95 in 1:20-cv-00445-LPS, 46 in 1:20-cv-00074-LPS) STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Joint Claim Construction Chart to February 17, 2021 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/16/21. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Feb 12, 2021 | 115 | Stipulation to EXTEND Time (11) Docket Text: STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Joint Claim Construction Chart to February 17, 2021 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 12, 2021 | 116 | Notice (Other) (2) Docket Text: NOTICE of of Change of Law Firm Affiliation by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. (Stamoulis, Stamatios) |
| Feb 1, 2021 | 114 | Notice of Service (15) Docket Text: NOTICE OF SERVICE of Novartis's Rebuttal Proposed Constructions of Claim Terms and Intrinsic Evidence filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 29, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (198 in 1:20-md-02930-LPS) (44 in 1:20-cv-00074-LPS, 92 in 1:20-cv-00445-LPS, 47 in 1:20-cv-00415-LPS, 113 in 1:19-cv-02053-LPS, 66 in 1:19-cv-02021-LPS, 194 in 1:19-cv-01979-LPS) STIPULATION TO EXTEND TIME for completion of production of documents to March 15, 2021 filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 1/28/21. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Jan 27, 2021 | 113 | Stipulation to EXTEND Time (12) Docket Text: STIPULATION TO EXTEND TIME for completion of production of documents to March 15, 2021 - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Seaman, John) |
| Jan 22, 2021 | 112 | Notice of Service (14) Docket Text: NOTICE OF SERVICE of (1) Novartis's First Supplemental Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-7) and (2) Novartis's First Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 15, 2021 | 111 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd.s First Set of Individual Interrogatories (Nos. 1-3) to Plaintiff Novartis Pharmaceuticals Corporation filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Jan 11, 2021 | 110 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove Peter J. Fallon as co-counsel. Reason for request: retired from Locke Lord. (Poff, Adam) |
| Jan 9, 2021 | 109 | Notice of Service (6) Docket Text: NOTICE OF SERVICE of Defendants Preliminary Claim Constructions and Supporting Evidence filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Jan 7, 2021 | 108 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s First Supplemental Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Jan 6, 2021 | 107 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's First Supplemental Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Dec 7, 2020 | 106 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Joint Invalidity Contentions filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Dr. Reddys Laboratories, Inc., Hetero USA Inc..(Ormerod, Eve) |
| Dec 4, 2020 | 105 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants Joint Initial Invalidity Contentions Under Local Patent Rules filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) |
| Nov 19, 2020 | 100 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth) |
| Nov 19, 2020 | 101 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Torrent's Objections and Responses to Plaintiff's Second Set of Interrogatories (Nos. 3-5) and 2) Hetero's Objections and Responses to Plaintiff's Second Set of Interrogatories (Nos. 3-5) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc..(Ormerod, Eve) |
| Nov 19, 2020 | 102 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Second Set of Interrogatories (Nos. 3-5) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Poff, Adam) |
| Nov 19, 2020 | 103 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Response to Plaintiffs Second Set of Interrogatories (Nos. 3-5) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) |
| Nov 19, 2020 | 104 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Objections and Responses to Novartiss Second Set of Interrogatories (Nos. 3-5) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Nov 16, 2020 | 99 | Notice of Service (13) Docket Text: NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' First Set of Interrogatories (Nos. 1-7) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 5, 2020 | 98 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Response to Plaintiffs First Set of Interrogatories (Nos. 1-2) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) |
| Oct 22, 2020 | 94 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Torrent's Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-2) and 2) Hetero's Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-2) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc..(Belgam, Neal) |
| Oct 22, 2020 | 95 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss First Set of Interrogatories (Nos. 1 and 2) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth) |
| Oct 22, 2020 | 96 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's First Set of Interrogatories (Nos. 1-2) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Oct 22, 2020 | 97 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Objections and Responses to Novartiss First Set of Interrogatories (Nos. 1-2) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Oct 21, 2020 | 93 | Notice of Service (20) Docket Text: NOTICE OF SERVICE of (1) Novartiss Second Set of Interrogatories to Defendants (Nos. 3-5) and (2) Plaintiffs Initial Infringement Chart Against Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Oct 20, 2020 | 92 | Notice of Service (14) Docket Text: NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-108) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Oct 16, 2020 | 91 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Response to Plaintiffs Fourth Set of Requests for the Production of Documents and Things Nos. (75-80) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) |
| Oct 15, 2020 | 90 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendants First Set of Interrogatories (Nos. 1-7) to Plaintiff Novartis Pharmaceuticals Corporation filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Oct 9, 2020 | 89 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) MSN Pharmaceuticals Inc., MSN Laboratories Private Limiteds and MSN Life Sciences Private Limiteds Response to Plaintiffs Third Set of Requests for the Production of Documents and Things and (2) MSN Pharmaceuticals Inc., MSN Laboratories Private Limiteds and MSN Life Sciences Private Limiteds Response to Plaintiffs Second Set of Requests for the Production of Documents and Things filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) |
| Oct 6, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Michael J. Gaertner, James T. Peterka, Nina Vachhani for Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS(kmd) |
| Oct 5, 2020 | 86 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Responses and Objections to Plaintiff's Second Set of Requests for the Production of Documents and Things (Nos. 15-61) and 2) Responses and Objections to Plaintiff's Third Set of Requests for the Production of Documents and Things (Nos. 62-74) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc..(Ormerod, Eve) |
| Oct 5, 2020 | 87 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Defendant Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Second Set of Requests for the Production of Documents and Things (Nos. 21-67); and 2) Defendant Novugen Pharma (Malaysia) Sdn. Bhd.s Objections and Responses to Novartiss Third Set of Requests for the Production of Documents and Things (Nos. 68-86) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth) |
| Oct 5, 2020 | 88 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Second Set of Requests to Zydus for the Production of Documents and Things (Nos. 15-61); and 2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's Third Set of Requests to Zydus for the Production of Documents and Things (Nos. 62 - 74); filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Oct 2, 2020 | 85 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss Third Set of Requests for the Production of Documents and Things (Nos. 62-74) and (2) Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss Second Set of Requests for the Production of Documents and Things (Nos. 15-61) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Oct 1, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (84 in 1:19-cv-02053-LPS, 119 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Michael J. Gaertner, James T. Peterka, and Nina Vachhani filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 10/1/20. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Sep 30, 2020 | 84 | Motion for Leave to Appear Pro Hac Vice (7) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Michael J. Gaertner, James T. Peterka, and Nina Vachhani - filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Swadley, Beth) |
| Sep 28, 2020 | 80 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's First Set of Requests for the Production of Documents and Things (Nos. 1-14) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Sep 28, 2020 | 81 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Novugen Pharma (Malaysia) Sdn. Bhd.'s Objections and Responses to Novartis's First Set of Requests for the Production of Documents and Things (Nos. 1-20) filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth) |
| Sep 28, 2020 | 82 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Response to Plaintiffs First Set of Requests for the Production of Documents and Things filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) |
| Sep 28, 2020 | 83 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Objections and Responses to Novartiss First Set of Requests for the Production of Documents and Things (Nos. 1-14) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Sep 22, 2020 | 79 | Notice of Service (17) Docket Text: NOTICE OF SERVICE of Novartis's First Set of Interrogatories to Defendants (Nos. 1-2) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Sep 18, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (24 in 1:20-cv-00074-LPS, 80 in 1:20-md-02930-LPS, 67 in 1:19-cv-02053-LPS, 40 in 1:19-cv-02021-LPS, 68 in 1:20-cv-00445-LPS, 122 in 1:19-cv-01979-LPS, 26 in 1:20-cv-00415-LPS) STIPULATED PROTECTIVE ORDER. Signed by Judge Leonard P. Stark on 9/14/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Sep 18, 2020 | 78 | Scheduling Order (24) Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Fact Discovery completed by 10/20/2021. Status Report due by 11/3/2021. Joint Claim Construction Brief due by 5/21/2021. A Markman Hearing is set for 6/7/2021 at 12:30 PM in Courtroom 6B before Judge Leonard P. Stark. A Final Pretrial Conference is set for 8/26/2022 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. A 12-day Bench Trial is set for 9/8/2022 at 08:30 AM in Courtroom 6B before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 9/14/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Sep 17, 2020 | 76 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-108) to Plaintiff Novartis Pharmaceuticals Corporation filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) |
| Sep 17, 2020 | 77 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Objections and Responses to Plaintiff's First Set of Requests for Production of Documents and Things (Nos. 1-14) filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc..(Ormerod, Eve) |
| Sep 16, 2020 | 75 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Novartiss Fourth Set of Requests to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, & MSN Life Sciences Private Limited for the Production of Documents and Things (Nos. 75-78) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Sep 11, 2020 | 74 | Proposed Order (26) Docket Text: PROPOSED ORDER Scheduling by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Sep 9, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (42 in 1:19-cv-02021-LPS, 71 in 1:20-cv-00445-LPS, 73 in 1:19-cv-02053-LPS, 132 in 1:19-cv-01979-LPS, 26 in 1:20-cv-00074-LPS, 29 in 1:20-cv-00415-LPS, 95 in 1:20-md-02930-LPS) STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Revised Proposed Scheduling Order to September 11, 2020 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 9/8/20. Associated Cases: 1:20-md-02930-LPS et al. (ntl) |
| Sep 4, 2020 | 73 | Stipulation to EXTEND Time (10) Docket Text: STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Revised Proposed Scheduling Order to September 11, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Sep 3, 2020 | 70 | Notice of Service (19) Docket Text: NOTICE OF SERVICE of (1) Novartiss Second Set of Requests to Defendants for the Production of Documents and Things ; and (2) Novartiss Third Set of Requests to Defendants for the Production of Documents and Things filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Sep 3, 2020 | 71 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of correspondence regarding Drug Master files and samples filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Sep 3, 2020 | 72 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of correspondence pursuant to the Court's August 24, 2020 Order regarding Drug Master files and samples filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth) |
| Aug 31, 2020 | 67 | Proposed Order (30) Docket Text: PROPOSED ORDER Stipulated Protective Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 31, 2020 | 68 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Letter Regarding the Drug Master File for Torrent and Hetero's API and Drug or Product Samples filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Torrent Pharmaceuticals Ltd., Hetero USA Inc..(Ormerod, Eve) |
| Aug 31, 2020 | 69 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of correspondence pursuant to the Courts August 24, 2020 Order regarding Drug Master Files and samples filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Aug 28, 2020 | 66 | Notice of Service (19) Docket Text: NOTICE OF SERVICE of Novartis's First Set of Requests to Defendants for the Production of Documents and Things filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 27, 2020 | 65 | Transcript (66) Docket Text: Official Transcript of Telephone Conference held on August 24, 2020 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, e-mail: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/17/2020. Redacted Transcript Deadline set for 9/28/2020. Release of Transcript Restriction set for 11/25/2020. (bpg) |
| Aug 25, 2020 | N/A | Order (0) Docket Text: ORAL ORDER: For the reasons stated during the teleconference on August 24, 2020, IT IS HEREBY ORDERED THAT a revised version of the proposed protective order is due on August 31, 2020, and a revised version of the proposed scheduling order is due on September 4, 2020, both incorporating the dates and decisions the Court announced during the hearing, including that the bench trial (not to exceed 12 days) will be held between September 8 and 23, 2022. ORDERED by Judge Leonard P. Stark on 8/25/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Aug 24, 2020 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 8/24/2020. (Court Reporter B. Gaffigan.) Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Aug 20, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (61 in 1:19-cv-02053-LPS, 69 in 1:20-md-02930-LPS, 63 in 1:20-cv-00445-LPS, 19 in 1:20-cv-00074-LPS, 112 in 1:19-cv-01979-LPS, 21 in 1:20-cv-00415-LPS, 33 in 1:19-cv-02021-LPS) STIPULATION TO EXTEND TIME for parties to submit a proposed scheduling order, proposed protective order, and letters regarding the disputed provisions to August 18, 2020 at 12:00 p.m. EST filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 8/20/20. Associated Cases: 1:19-cv-01979-LPS et al. (ntl) |
| Aug 18, 2020 | 62 | Main Document (10) Docket Text: Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Regarding Disputed Provisions of Proposed Scheduling Order. (Attachments: # (1) Exhibit A-K, # (2) Text of Proposed Order [Reflecting Parties' Disagreements])(Silver, Daniel) |
| Aug 18, 2020 | 62 | Exhibit A-K (224) |
| Aug 18, 2020 | 62 | Text of Proposed Order [Reflecting Parties' Disagreements] (37) |
| Aug 18, 2020 | 63 | Main Document (9) Docket Text: Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Disputed Provisions of Proposed Protective Order. (Attachments: # (1) Exhibit 1-2, # (2) Text of Proposed Order [Reflecting Parties' Disagreements])(Silver, Daniel) |
| Aug 18, 2020 | 63 | Exhibit 1-2 (16) |
| Aug 18, 2020 | 63 | Text of Proposed Order [Reflecting Parties' Disagreements] (49) |
| Aug 17, 2020 | 61 | Stipulation to EXTEND Time (11) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a proposed scheduling order, proposed protective order, and letters regarding the disputed provisions to August 18, 2020 at 12:00 p.m. EST - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 31, 2020 | 60 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of MSN Laboratories Private Limiteds and MSN Pharmaceuticals Inc.s Initial Rule 26(a)(1) Disclosures; and MSN Laboratories Private Limiteds and MSN Pharmaceuticals Inc.s Initial ESI Disclosures filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) |
| Jul 29, 2020 | N/A | Order Setting Teleconference (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that a Scheduling and Discovery Telephone Conference is set for August 24, 2020 at 9:30 AM. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. The parties shall confer and submit a proposed schedule, proposed protective order, and letter(s) regarding the disputed provisions, all by no later than August 17. ORDERED by Judge Leonard P. Stark on 7/29/20. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00445-LPS (ntl) |
| Jul 27, 2020 | 57 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limiteds Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; and 2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limiteds Fed. R. Civ. P. 26(a)(1) Initial Disclosures filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Swadley, Beth) |
| Jul 27, 2020 | 58 | Notice of Service (13) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs Rule 26(A)(1) Initial Disclosures; (2) Plaintiffs Initial Paragraph 3 Disclosures Regarding Electronic Systems Information; and (3) Plaintiffs Identification of Asserted patents and Accused Products pursuant to Paragraph 4(a) of the Delaware Default Standard for Discovery filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 14, 2020 | 56 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of 1) Novugen Pharma (Malaysia) Sdn. Bhd.s Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; and 2) Novugen Pharma (Malaysia) Sdn. Bhd.s Fed. R. Civ. P. 26(a)(1) Initial Disclosures filed by Novugen Pharma (Malaysia) Sdn. Bhd..(Swadley, Beth) |
| Jul 8, 2020 | 55 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Rule 26(a) Initial Disclosures and Paragraph 3 Disclosures filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc..(Ormerod, Eve) |
| Jul 6, 2020 | 53 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Core Technical Document Production filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc..(Ormerod, Eve) |
| Jul 6, 2020 | 54 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Core Technical Documents filed by Dr. Reddy's Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Dr. Reddys Laboratories, Inc..(Stamoulis, Stamatios) |
| Jun 26, 2020 | 52 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Core Technical Documents filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Poff, Adam) |
| Jun 15, 2020 | 51 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Discovery Disclosures Pursuant to the District of Delawares Default Standard and Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Weinblatt, Richard) |
| May 5, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Alan B. Clement, Zhibin Li, and Peter J. Fallon for Novugen Pharma (Malaysia) Sdn. Bhd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-02053-LPS(sam) |
| Apr 21, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Edward D. Pergament for Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS(sam) |
| Apr 20, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (18 in 1:20-md-02930-LPS, 50 in 1:19-cv-02053-LPS) MOTION for Pro Hac Vice Appearance of Attorney Alan B. Clement, Peter J. Fallon and Zhibin Li filed by Novugen Pharma (Malaysia) Sdn. Bhd. Signed by Judge Leonard P. Stark on 4/20/20. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Apr 20, 2020 | 50 | Motion for Leave to Appear Pro Hac Vice (7) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Alan B. Clement, Peter J. Fallon and Zhibin Li - filed by Novugen Pharma (Malaysia) Sdn. Bhd.. (Swadley, Beth) |
| Apr 9, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (49 in 1:19-cv-02053-LPS, 12 in 1:20-md-02930-LPS) MOTION for Pro Hac Vice Appearance of Attorney Edward D. Pergament filed by Hetero USA Inc.,, Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III. Signed by Judge Leonard P. Stark on 4/9/20. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Apr 9, 2020 | 49 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Edward D. Pergament - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc.. (Ormerod, Eve) |
| Apr 3, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Kenneth S. Canfield for Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lak) |
| Apr 2, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (8 in 1:20-md-02930-LPS, 48 in 1:19-cv-02053-LPS) MOTION for Pro Hac Vice Appearance of Attorney Kenneth S. Canfield filed by Hetero USA Inc.,, Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III. Signed by Judge Leonard P. Stark on 4/2/20. Associated Cases: 1:19-cv-02053-LPS, 1:20-md-02930-LPS (ntl) |
| Apr 1, 2020 | 48 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Kenneth S. Canfield - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,, Hetero USA Inc.. (Ormerod, Eve) |
| Mar 31, 2020 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Case from West VA was inadvertently opened as 20-MD-445. The proper case number is 20-CV-445. Associated Cases: 1:20-cv-00445-LPS et al.(rwc) |
| Mar 30, 2020 | 47 | Remark - MDL Notice to Counsel (1) Docket Text: NOTICE TO COUNSEL: MDL No. 1:20-md-2930 has been opened and assigned to the Honorable Leonard P. Stark. Attorneys of record who will be electronically filing documents may use the attached form to register for a CM/ECF login and password or they may continue to go through their Local Counsel. Please see the docket for further entries. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS(rwc) |
| Mar 27, 2020 | N/A | Remark - MDL Member (0) Docket Text: NOTICE: Documents relating to all actions should be filed on the master docket sheet (20-MD-2930) AND on the docket sheet of each individual action. Documents relating to two or more, but not all, individual actions should be filed on the master docket sheet, and on the docket sheet of each affected individual action. Documents affecting a single individual action should be filed on the docket sheet of that action and on the master docket sheet. Associated Cases: 1:20-md-02930-LPS, 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS(rwc) |
| Mar 27, 2020 | 46 | Order (4) Docket Text: CERTIFIED TRANSFER ORDER re: 20-MD-2930 - signed 3/27/20 by Clerk, MDL Panel. (rwc) |
| Mar 11, 2020 | 45 | Notice (Other) (1) Docket Text: NOTICE of Withdrawal of Appearance (Jennifer M. Rutter) by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc. (Rutter, Jennifer) |
| Feb 28, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jared L. Stringham, and Nicholas N. Kallas for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00074-LPS(sam) |
| Feb 27, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (63 in 1:19-cv-01979-LPS, 43 in 1:19-cv-02053-LPS, 23 in 1:19-cv-02021-LPS, 10 in 1:20-cv-00074-LPS) MOTION for Pro Hac Vice Appearance of Attorney Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 2/27/20. Associated Cases: 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00074-LPS (ntl) |
| Feb 27, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christina Schwarz for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:19-cv-01979-LPS, 1:19-cv-02021-LPS, 1:19-cv-02053-LPS, 1:20-cv-00074-LPS(kmd) |
| Feb 27, 2020 | 44 | Answer to Counterclaim (23) Docket Text: ANSWER to [34] Answer to Complaint, Counterclaim / Plaintiff's Answer to Dr. Reddy's Laboratories, Ltd.'s and Dr. Reddy's Laboratories, Inc.'s Counterclaims by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 25, 2020 | 43 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham)(Silver, Daniel) |
| Feb 25, 2020 | 43 | Certifications for Nichols N. Kallas, Christina Schwarz, and Jared L. Stringham (3) |
| Feb 18, 2020 | 42 | Answer to Counterclaim (16) Docket Text: ANSWER to [30] Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 12, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher D. Jones for Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
| Feb 7, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [33] Stipulation of Dismissal -- Party Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited terminated. Attorney David Ellis Moore and Bindu Ann George Palapura terminated. Signed by Judge Leonard P. Stark on 2/7/20. (ntl) |
| Feb 7, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [41] MOTION for Pro Hac Vice Appearance of Attorney Autumn N. Nero, Bryan D. Beel, and Christopher D. Jones filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd. Signed by Judge Leonard P. Stark on 2/7/20. (ntl) |
| Feb 6, 2020 | 34 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,, , COUNTERCLAIM against All Plaintiffs by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) |
| Feb 6, 2020 | 35 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Dr. Reddys Laboratories SA for Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd. filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Stamoulis, Stamatios) |
| Feb 6, 2020 | 36 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,, and Affirmative Defenses by Novugen Pharma (Malaysia) Sdn. Bhd..(Poff, Adam) |
| Feb 6, 2020 | 37 | Disclosure Statement (4) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novugen Pharma Limited for Novugen Pharma (Malaysia) Sdn. Bhd. filed by Novugen Pharma (Malaysia) Sdn. Bhd.. (Poff, Adam) |
| Feb 6, 2020 | 38 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,, and Affirmative Defenses by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Poff, Adam) |
| Feb 6, 2020 | 39 | Disclosure Statement (3) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Cadila Healthcare Ltd.. (Poff, Adam) |
| Feb 6, 2020 | 40 | Disclosure Statement (3) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Cadila Healthcare Limited for Zydus Pharmaceuticals (USA) Inc. filed by Zydus Pharmaceuticals (USA) Inc.. (Poff, Adam) |
| Feb 6, 2020 | 41 | Motion for Leave to Appear Pro Hac Vice (7) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Autumn N. Nero, Bryan D. Beel, and Christopher D. Jones - filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Stamoulis, Stamatios) |
| Feb 5, 2020 | 33 | Stipulation of Dismissal (2) Docket Text: STIPULATION of Dismissal by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Moore, David) |
| Jan 28, 2020 | 32 | Answer to Counterclaim (27) Docket Text: ANSWER to [27] Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 27, 2020 | 30 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,, Additional Defenses, COUNTERCLAIM of Hetero USA, Inc. against Novartis Pharmaceuticals Corporation by Hetero Labs Limited, Hetero USA Inc., Hetero Labs Limited Unit III.(Ormerod, Eve) |
| Jan 27, 2020 | 31 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Hetero Labs Ltd. for Hetero Labs Limited Unit III, Hetero USA Inc. filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.. (Ormerod, Eve) |
| Jan 17, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [29] STIPULATION TO EXTEND TIME for Mylan to answer, move or otherwise respond to the Complaint to February 6, 2020 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Mylan Inc. Signed by Judge Leonard P. Stark on 1/17/20. (ntl) |
| Jan 16, 2020 | 29 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Mylan to answer, move or otherwise respond to the Complaint to February 6, 2020 - filed by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Palapura, Bindu) |
| Jan 8, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [26] Joint STIPULATION TO EXTEND TIME to Move, Answer or otherwise Respond to the Complaint to February 6, 2020 filed by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III. Signed by Judge Leonard P. Stark on 1/8/2020. (ntl) |
| Jan 7, 2020 | 27 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., MSN Laboratories Private Limited.(Stamoulis, Stamatios) |
| Jan 7, 2020 | 28 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Laboratories Pvt. Ltd. for MSN Pharmaceuticals Inc. filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Stamoulis, Stamatios) |
| Jan 6, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [23] STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to January 21, 2020 filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Mylan Inc., [25] STIPULATION TO EXTEND TIME for Defendants Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd. to answer, move, or otherwise respond to the Complaint to February 6, 2020 filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd. Signed by Judge Leonard P. Stark on 1/6/20. (ntl) |
| Jan 6, 2020 | 26 | Stipulation to EXTEND Time (2) Docket Text: Joint STIPULATION TO EXTEND TIME to Move, Answer or otherwise Respond to the Complaint to February 6, 2020 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.. (Ormerod, Eve) |
| Jan 3, 2020 | 23 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to January 21, 2020 - filed by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Moore, David) |
| Jan 3, 2020 | 24 | Notice of Appearance (2) Docket Text: NOTICE of Appearance by Bindu Ann George Palapura on behalf of Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Palapura, Bindu) |
| Jan 3, 2020 | 25 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Defendants Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd. to answer, move, or otherwise respond to the Complaint to February 6, 2020 - filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Stamoulis, Stamatios) |
| Dec 20, 2019 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [22] MOTION for Pro Hac Vice Appearance of Attorney Dmitry V. Shelhoff. Ph.D. filed by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III. Signed by Judge Leonard P. Stark on 12/20/19. (ntl) |
| Dec 20, 2019 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Dmitry V. Shelhoff for Hetero Labs Limited, Hetero Labs Limited Unit III,and Hetero USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
| Dec 19, 2019 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [20] Joint STIPULATION TO EXTEND TIME for Defendants to answer, move, or otherwise respond to the Complaint to February 6, 2020 filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 12/19/19. (ntl) |
| Dec 19, 2019 | 21 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Eve H. Ormerod on behalf of Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc. (Ormerod, Eve) |
| Dec 19, 2019 | 22 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Dmitry V. Shelhoff. Ph.D. - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.. (Ormerod, Eve) |
| Dec 18, 2019 | 20 | Stipulation to EXTEND Time (2) Docket Text: Joint STIPULATION TO EXTEND TIME for Defendants to answer, move, or otherwise respond to the Complaint to February 6, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Dec 12, 2019 | 6 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Cadila Healthcare Ltd. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 7 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Dr. Reddys Laboratories, Inc. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 8 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Dr. Reddys Laboratories, Ltd. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 9 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Hetero Labs Limited Unit III waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 10 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Hetero Labs Limited waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 11 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Hetero USA Inc. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 12 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For MSN Laboratories Private Limited waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 13 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For MSN Life Sciences Private Limited waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 14 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For MSN Pharmaceuticals Inc. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 15 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Mylan Inc. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 16 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Mylan Laboratories Limited waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 17 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Mylan Pharmaceuticals Inc. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 18 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Novugen Pharma (Malaysia) Sdn. Bhd. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Dec 12, 2019 | 19 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novartis Pharmaceuticals Corporation: For Zydus Pharmaceuticals (USA) Inc. waiver sent on 11/8/2019, answer due 1/7/2020. (Silver, Daniel) |
| Nov 6, 2019 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Oct 29, 2019 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (nmg) |
| Oct 29, 2019 | 1 | Main Document (65) Docket Text: COMPLAINT for PATENT INFRINGEMENT filed against Cadila Healthcare Ltd., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Novugen Pharma (Malaysia) Sdn. Bhd., Zydus Pharmaceuticals (USA) Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2766453.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-D, # (2) Civil Cover Sheet)(nmg) |
| Oct 29, 2019 | 1 | Exhibit A-D (63) |
| Oct 29, 2019 | 1 | Civil Cover Sheet (2) |
| Oct 29, 2019 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Oct 29, 2019 | 3 | ANDA Form (3) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: See Attached. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 7/7/2023. (nmg) |
| Oct 29, 2019 | 4 | Patent/Trademark Report to Commissioner (2) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659; 8,796,331; 8,877,938; 9,388,134. (nmg) |
| Oct 29, 2019 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (nmg) |
| Oct 29, 2019 | 1 | Complaint* (1) |
